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The rapid increase in allergic diseases in developed, high-income countries during
recent decades is attributed to several changes in the environment such as urbanization
and improved hygiene. Such changes are followed by diminished exposure to microbes
during infancy. This relative lack of microbial stimulation is connected to a delay in
maturation of the infantile immune system and seems to predispose especially
genetically prone infants to allergic diseases. Probiotics, which are live, ingestible
health-promoting microbes, may compensate for the lack of microbial stimulation of the
developing gut immune system and may thus be beneficial in prevention of allergies.
Prebiotics, which are indigestible nutrients for humans, promote the growth and activity
of a number of bacterial strains considered beneficial for the gut. Probiotics and
prebiotics administered together are called synbiotics and are believed to act
synergistically.
In a large cohort of infants at hereditary risk for allergies we studied whether
probiotics and prebiotics administered in early life prevent allergic diseases from
developing. We also evaluated their safety and their effects on common childhood
infections, vaccine antibody responses, and intestinal immune markers.
Between November 2000 and March 2003, we randomized for a double-blind
placebo-controlled trial 1 223 pregnant women living in suburban Helsinki and carrying
fetuses at increased risk for allergies. These mothers used a mixture of four probiotic
bacteria (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve
Bb99, and Propionibacterium freudenreichii ssp. shermanii  JS) or a placebo, from their
36th week of gestation. Their infants received the same probiotics plus prebiotic
galacto-oligosaccharides for 6 months. The 2-year follow-up consisted of clinical
examinations and allergy tests (skin prick tests and serum antigen-specific IgE-
antibodies), fecal and blood sampling, and regular questionnaires.
In the probiotic group compared to placebo, fecal recovery of lactobacilli (98% vs.
56%, P<0.001) and of bifidobacteria (98% vs. 86%, P=0.039) was more frequent, and
fecal counts of probiotic bacteria were higher (P<0.001) at 3 and 6 months, showing the
success of the intervention. However, recovery of the probiotics in the feces was
transient, and no differences in the colonization patterns occurred at 2 years.
A total of 925 infants participated in the 2-year follow-up. The cumulative incidence
of any allergic disease (food allergy, eczema, asthma, allergic rhinitis) did not differ
significantly between the probiotic (32%) and the placebo (35%) groups. However,
probiotics compared to placebo tended to reduce all atopic (IgE-associated) diseases
(14% vs. 19%), (OR 0.71, 95% CI 0.50 to 1.00; P=0.052).
Eczema, which was the most common manifestation (88%) of all allergic diseases
by age 2 years, occurred less frequently in the probiotic (26%) than in the placebo
group (32%), (OR 0.74, 95% CI 0.55 to 0.98; P=0.035). The preventive effect was
more pronounced against atopic (IgE-associated) eczema, which, of all atopic diseases,
accounted for 92%. The incidence of atopic eczema in the probiotic group (12%) was
significantly lower than in the placebo group (18%), (OR 0.66, 95% CI 0.46 to 0.95;
P=0.025). The relative risk reduction of eczema was thus 26% and of atopic eczema
34%. To prevent one case of eczema, the number of mother-infant pairs needed to treat
was 16, and to prevent one case of atopic eczema, was 19.
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Probiotic treatment was safe without any undesirable outcome for neonatal
morbidity, feeding-related behavior, serious adverse events, or growth. Probiotics
seemed to enhance the child’s resistance to respiratory infections. Fewer infants in the
probiotic (23%) than in the placebo (28%) group received antibiotics during their first 6
months of life (P=0.049), and thereafter to age 2 years suffered from fewer respiratory
tract infections (geometric mean 3.7 vs. 4.2; P=0.009).
Vaccine antibodies examined in 87 infants showed no adverse effects of probiotics
on tetanus, diphtheria, or Haemophilus influenzae type B (Hib) vaccinations. In the
probiotic group compared to placebo, the first Hib-vaccine dose more frequently
produced protective ( 1µg/ml) Hib IgG antibody concentrations (50% vs. 21%;
P=0.020), and the geometric mean Hib IgG concentrations tended to be higher
(P=0.064).
Studying fecal immune markers in 237 infants, we discovered that high (upper
tertiles) fecal immunoglobulin A (IgA) concentrations at age 6 months protected from
atopic (IgE-associated) diseases by age 2 years. Probiotics led to increased fecal 1-
antitrypsin (P=0.001) and calprotectin (adjusted P=0.045) concentrations and tended to
augment fecal tumor necrosis factor-  (P=0.099) and fecal IgA concentrations
(P=0.085).
In conclusion, although feeding probiotics to high-risk newborn infants showed no
preventive effect on the cumulative incidence of any allergic diseases by age 2, they
apparently prevented eczema. This probiotic effect was more pronounced among IgE-
sensitized infants. The treatment was safe and seemed to stimulate maturation of the
immune system as indicated by increased resistance to respiratory infections and
improved vaccine antibody responses. Stimulation of the immune system maturation
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DTwP: diphtheria, tetanus and whole cell pertussis vaccine
HbOC: PRP conjugated to Corynebacterium diphtheriae toxin
CRM19
Hib: Haemophilus influenzae type B
Ig: immunoglobulin
INF- : interferon- 
IL: interleukin
OR: odds ratio
PRP: polysaccharide polyribosylribitol phosphate
PRP-T: PRP conjugated to tetanus toxoid
SCORAD: Severity Scoring of Atopic Dermatitis
Th: T-helper cell
TNF- : tumor necrosis factor- 
TLR toll-like receptors
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1. Introduction
The marked rise in the prevalence of allergic diseases since the 1950’s parallels the
postindustrial changes in lifestyle, characterized by a high standard of hygiene and
reduced exposure to microbes in daily environments (Beasley et al., 1998; Bach, 2002;
Latvala et al., 2005). The “hygiene hypothesis,” which claims that unhygienic
conditions and infections confer protection against the development of allergies
(Gerrard et al., 1976; Strachan, 1989), is supported by wider epidemiological evidence
(Alfvén et al., 2006). Even so, heredity is a strong positive predictive factor for allergic
diseases (Prescott et al., 2003).
With progressive Westernization, colonization patterns of the gut microbiota have
evolved (Adlerberth et al., 1991, 2006). Gut microbiota, which offer the strongest
microbial stimulation throughout life, are a prerequisite for the initial maturation of our
largest immunological organ, which is the gut. A mature immune system separates
pathogens from harmless microbial and food antigens and maintains immune
homeostasis, disruption of which may result in allergic diseases (Penders et al., 2007).
Differences in the composition of gut microflora between allergic and healthy infants
even before establishment of any allergic disease (Björkstén et al., 2001), together with
the pre-symptomatic immune system dysregulation among atopics, suggests that
preventive procedures should be started in early life (Prescott et al., 2003).
The idea of using lactic acid bacteria to promote health is ancient. In 1910, in his
search for prolongation of life, a modern immunologist, Élie Metchnikoff, at the Pasteur
Institute in Paris suggested that senility caused by detrimental metabolism of intestinal
microflora may be inhibited by lactic acid bacteria in fermented milk (Metchnikoff,
1910). Yet decades elapsed before the beneficial bacteria— called probiotics, based on
the Greek term “for life”— became a subject of intensive research. Prebiotics are non-
digestible food ingredients which promote the growth and activity of probiotics in the
gut (Gibson and Roberfroid, 1995).
Live probiotic bacteria offer some compensation for a lack of microbial stimulation
to our immune system. In infants who are genetically at increased risk for developing
allergies, perinatal administration of probiotics has stimulated maturation of the
immune function (Walker et al., 2006). Probiotics have ameliorated already manifest
childhood allergies, particularly eczema (Majamaa and Isolauri, 1997). Their beneficial
effects have been strain-specific and have shown a more pronounced emergence in
children who are sensitized to common environmental or food antigens (Viljanen et al.,
2005c; Rosenfeldt et al., 2003; Weston et al., 2005; Sistek et al., 2006). In the first
study on preventing eczema in children at hereditary risk for allergy, probiotics showed
great promise. Lactobacillus rhamnosus GG, given to pregnant mothers and to their
newborn babies for 6 months from birth, halved the incidence of eczema by age 2 years.
However, sensitization remained unaffected (Kalliomäki et al., 2001b).
The present study was started in 2000 when no information on the possibility of
preventing allergies by probiotics had appeared. Since then, information on probiotics
has almost exponentially increased, including doubts about and criticism of the
enthusiasm for probiotics. The main purpose of this study was to discover whether
probiotics and prebiotics administered to a large cohort of pregnant mothers and to their
newborn infants at hereditary risk for allergy could prevent the development of allergic
diseases.
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2. Review of the literature
2.1 Allergy
2.1.1 Definition
Allergy, atopy, and sensitization
The term “allergy” was originally introduced in 1906 by von Pirquet to denote an
antigen-induced biological response which may lead either to immunity or to allergic
disease. Today, allergy denotes immunologically initiated hypersensitivity reactions to
harmless antigens (Kay, 2001). Classified on the basis of mechanisms involved,
allergies are further divided into immunoglobulin (Ig)E-mediated and non-IgE-
mediated reactions (Johansson et al., 2004).
Before the discovery of IgE in 1967, atopy was applied to allergic conditions that
occur in families (Johansson, 1967). Today the term “atopy” is applied to the hereditary
tendency to produce excessive IgE antibodies in response to common environmental
allergens, mostly proteins, and to develop typical symptoms such as eczema, asthma, or
rhino-conjunctivitis. Any allergic disease associated with IgE-sensitization is atopic
(Johansson et al., 2004).
Sensitization refers to excessive production of IgE antibodies during common
allergen exposure measured by skin prick tests or by serum antigen-specific IgE
antibodies (Johansson et al., 2004). Antigens and immune modulating proteins that
cross the placenta may influence the developing immune system (Jones et al., 2002),
but primary sensitization already developing in utero has not been confirmed
(Bønnelykke et al., 2008).  Sensitized infants are at increased risk for developing
symptomatic allergies and for more slowly outgrowing their childhood allergic diseases.
They are the most probable subjects of the “atopic march” leading from food allergies
and eczema in early childhood to airway allergies at school age (Kusel et al., 2005).
Eczema
Eczema is a chronic itchy skin condition accompanied by poorly demarked erythema
with scaling, crusting, or lichenified surface changes on typical sites in children,
including flexural creases, the cheeks, and the outer surfaces of the legs and arms
(Williams et al., 1994). Since 1892 when first described by Besnier, a wealth of names
have been used for the condition (Novak et al., 2003). It is the first and most common
manifestation of allergic diseases in childhood, affecting 16% of Finnish children
before the age of 5 years (Lehtonen et al., 2003). In a Danish cohort of children born to
mothers with asthma, the cumulative incidence of eczema reached 31% at age 1 year,
41% at 2 years, and 44% at age 3 (Halkjaer et al., 2006). Indeed, majority of eczema
starts during the first year of life, but most children outgrow their eczema before
adulthood (Kusel et al., 2005; Gustafsson et al., 2000; Novak et al., 2003).
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According to the revised nomenclature for allergy for global use, atopic eczema
denotes eczema in IgE-sensitized individuals (Johansson et al., 2004). The atopic
variant of eczema occurs early in life and is a strong positive predictive factor for later
development of allergic asthma and rhinitis (Kusel et al., 2005; Gustafsson et al., 2000).
The pathophysiology of eczema involves complex interactions between genetic,
environmental, and immunological mechanisms which are not yet fully understood
(Novak et al., 2003). Eczema may be considered a major disorder with great social,
emotional, and financial effects on any family. Intensive itching, sleeping disturbances,
daytime tiredness and irritability of the child, as well as parents’ exhaustion and
helplessness are easily underestimated (Kemp, 2003).
Food allergy
Food allergy is an early manifesting allergic disease, affecting 3 to 6 % of infants under
age 3. It accompanies approximately 35% of moderate to severe eczema (Sampson,
2003).  Antigens responsible for food allergy show high stability in the gastrointestinal
environment and are associated with regional dietary habits (Sampson, 2003). An
estimated 5 to 15% of infants show symptoms related to cow’s milk ingestion
(Vandenplas et al., 2007), but the incidence of cow’s milk allergy confirmed by
challenge tests is 2 to 3% (Vanto et al., 2004). Cow’s milk accounts for the majority of
childhood food allergies in Finland, where the incidence of cow’s milk allergy in a large
prospective unselected birth cohort in the 1990’s was 2% (Saarinen et al., 1999a).
 Relatively few food antigens (cow’s milk, egg, wheat, soy, fish, peanuts, and tree
nuts) account for most allergic reactions. Allergic reactions to food manifest on the skin
(eczema, urticaria), in the gastrointestinal tract (vomiting, diarrhea, constipation, pain),
and in the airways (wheezing, swelling), and may elicit life-threatening anaphylactic
reactions (Sampson, 2003; Sicherer, 2002). The majority of these hypersensitivity
reactions are mediated by IgE-antibodies. The delayed non-IgE mediated reactions are
more benign in nature, and children grow out of them earlier. Most children (80%)
recover from their food allergies before age 4 to 5 (Vanto et al., 2004; Sampson, 2003).
Asthma
Childhood asthma is a heterogeneous disease featuring repeated attacks of airway
obstruction (wheezing) triggered by exercise, allergens, and viral infections (Illi et al.,
2006). Depending on the region studied and diagnostic criteria used, prevalence of
asthma symptoms varies worldwide from 2.5 to 36%, with a male preponderance
(Beasley et al., 1998; Martinez et al., 1995; Weinmayr et al., 2007). Of Finnish school
children from 1994 to 1995, 4 to 7% reported ever having had physician-diagnosed
asthma (Pekkanen et al., 1997). According to the Finnish Social Insurance Institution’s
reimbursement registry, the prevalence of chronic asthma among Finnish children was
1.9% in 1994, 3.1% in 2002, and 2.6% in 2006 (Mäkelä et al., 2008).
Wheeze under the age of 3 may be classified as transient or persistent, the latter
representing asthma. Early transient wheeze in common viral infections relates to
maternal smoking and to small airways at birth and is outgrown before school-age. Of
infants with an early frequent wheeze, the 30 to 50% sensitized to food or to airborne
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allergens are at increased risk for persistent asthma, which is characterized by airway
inflammation and airway remodeling and results in impairment of lung function (Illi et
al., 2006). In addition to atopy, early predictive factors for persistent asthma at school
age are maternal asthma, exposure to tobacco smoke, eczema, and hay fever (Castro-
Rodríguez et al., 2000; Høst and Halken, 2000; Linneberg et al., 2006; Martinez et al.,
1995). Morbidity from chronic asthma and its costs are both high in the European
Union (Illi et al., 2006).
Allergic rhinitis
Allergic rhinitis is a disorder induced by IgE-mediated inflammation in the nasal
mucosa. The symptom triage includes sneezing, nasal blockage, and mucous discharge
recurrently during allergen contact (Bousquet et al., 2008). Allergic rhinitis is a late
event in the sequence of allergies and therefore relatively rare among children under age
2. Its prevalence in pre-school-aged children varies from 5 to 7% (Grize et al., 2006;
Wickman et al., 2002). In 1994-1995, among 11 607 schoolchildren aged 13 to14 years
in Finland the self-reported prevalence of rhino-conjunctivitis during the preceding year
was 16 to 23% (Remes et al., 1998). Allergic rhinitis causes major illness and disability,
affects sleep, school, and social life, and because of substantial indirect costs, its
economic impact is often underestimated (Bousquet et al., 2008).
2.1.2 Increased prevalence of allergies
The prevalence of allergic disease shows a worldwide increase that affects particularly
the high-income Westernized countries (Beasley et al., 1998; Weinmayr et al., 2007).
Among Finnish young men during 1966 to 2003, the prevalence of asthma increased
12-fold from 0.3 to 3.4%, and allergic rhinitis increased from <0.1 to 8.9%, while the
prevalence of eczema remained relatively stable (Latvala et al., 2005). In 1994-1995,
almost half the 11 607 Finnish teenagers questioned reported ever suffering from an
allergic disease (Remes et al., 1998). Because of their urbanization, developing
countries may be awaiting this allergy epidemic (Viinanen et al., 2007; Weinmayr et
al., 2007); however, areas of high allergy prevalence have noticed reversing trends and
plateauing incidences (von Hertzen and Haahtela, 2005; Björkstén et al., 2008).
2.1.3 Immunology of allergy
Fetal immunity, which is characterized by dominance of T helper (Th) 2-type signals
and weakness of Th1-type signals, is a prerequisite for normal pregnancy. The
immature antigen-presenting cell system of the fetus and inhibition of Th1-responses by
placental cytokines restrain fetal rejection by the mother. In infants with atopic heredity,
transition from the fetal Th2-dominance to adult Th1-type immunity is delayed
(Martinez and Holt, 1999).
Postnatal maturation of the Th1-type immunity depends on microbial stimulation
(Martinez and Holt, 1999). The immune system must distinguish exogenous pathogens
from commensal microflora (Rakoff-Nahoum et al., 2004), which are capable of
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attenuating and terminating pathogen-induced pro-inflammatory signaling (Neish et al.,
2000; Kelly et al., 2004). Antigen-presenting cells in the intestinal mucosa recognize
conserved microbe-associated molecular patterns, such as lipopolysaccharides,
endotoxin, lipoteichoicacid, peptidoglycans, and cytosine-phosphate-guanine
oligonucleotide (CpG) sequences of bacterial DNA, through molecular recognition
receptors termed Toll-like receptors (TLR) (Medzhitov et al., 1997; Rakoff-Nahoum et
al., 2004). Activated antigen-presenting cells then release a variety of signaling
mediators— cytokines— which communicate between the innate and the adaptive
immunity and direct the differentiation of naïve T-cells to antigen-specific memory
cells.
Bacteria captured by macrophages induce interleukin (IL)-12 secretion from
antigen-presenting cells, which promote differentiation of naïve T-cells in a Th1-
direction. Differentiated Th1 lymphocytes produce IL-2 and interferon–  (IFN- ) and
support pro-inflammatory reactions against viruses and bacteria. IFN-  also promotes
B-cells in producing antigen-specific IgG2, which facilitates pathogen recognition and
phagocytosis (Calder, 2007).
Differentiation of naïve T-cells to Th2 lymphocytes requires IL-4. Th2-responses
are targeted against helmintic worms, and the hallmarks of their activation are IL-4, IL-
5 and IL-13. Th2-cytokines activate eosinophils and promote B-cells to produce IgE.
Regulatory T-cells suppress both Th1 and Th2 type pro-inflammatory responses
through the anti-inflammatory cytokines IL-10 and TGF- . During certain genetic
predisposition and environmental exposures, skewing of the immunity in the Th1 or
Th2 direction breaks the immune homeostasis, resulting in autoimmune or allergic
diseases, respectively (Calder, 2007).
In neonates with allergic heredity, sustained Th2-skewed immunity maintains IgE-
responses against harmless environmental antigens (Marschan et al., 2008a; Holt et al.,
1992). Over-expression of IL-4 results in excessive production of IgE, and IL-5
activates eosinophils, which are important effector-cells in allergic reactions (Martinez
and Holt, 1999). Defective anti-inflammatory control by regulatory cells is considered
central to the failure to attenuate Th2-type responses (Ling et al., 2004; Hawrylowicz
and O'Garra, 2005; Dunstan et al., 2005). Although helminth infections strongly induce
Th2-type cytokines, they are not associated with allergy. Elevated anti-inflammatory
cytokines such as IL-10, observed in chronic helminth infections, correlate inversely
with allergies (Yazdanbakhsh et al., 2002). The atopic phenotype is also characterized
by immature Th1-type immunity distinguished by deficient INF-  secretion (Tang et al.,
1994; Dunstan et al., 2005) and delayed maturation of adaptive immunity in the light of
poor IgG responses to vaccines (Arkwright et al., 2000; Prescott et al., 1998).
2.1.4 Heredity
Allergy is a multifactorial disease in which heredity is the strongest predictive factor.
The risk for eczema increases 2-fold with one affected parent and 3-fold if both parents
are affected (Novak et al., 2003). Parental asthma elevates the risk for asthma 3- to 4-
fold (Illi et al., 2006; Martinez et al., 1995). That allergic diseases and sensitization
affect boys more frequently than girls (Linneberg et al., 2006; Rönmark et al., 2003)
and that the concordance rates for allergy are higher in monozygotic (85%) than in
dizygotic (21%) twins (Novak et al., 2003) supports the important role of genetic
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background. Genetics alone cannot explain the recent rapid increase in allergies, but
genes influence the way environment modifies early immune responses (Eder et al.,
2004; Bruce et al., 2008; Bisgaard et al., 2008)
2.1.5 Environmental factors
Mode of delivery
Cesarean delivery has been associated with childhood food allergy more among
children born to allergic mothers (Eggesbø et al., 2003). Cesarean section is also
associated with asthma at school-age, independent of heredity (Kero et al., 2002).
Controversial evidence showing no association between cesarean delivery and asthma
or atopy exists, as well (Maitra et al., 2004). The world-wide rising trend for cesarean
section— 17% of deliveries in Finland (Stakes, 2008), over 30% in the US, and up to
36% in Latin America (Hamilton et al., 2007; Villar et al., 2007)— may account for
some of the recent increase in allergies.
Exposure to tobacco smoke
Maternal smoking during pregnancy and exposure to tobacco smoke in childhood leads
to increased risk for wheezing and asthma (Jaakkola and Gissler, 2004; Linneberg et al.,
2006; Gergen et al., 1998). In Finland, 17% of fetuses are exposed to tobacco in utero
(Stakes, 2008), which together with consistent exposure to environmental tobacco-
smoke have an adjuvant effect on IgE-sensitization of high-risk infants during their first
3 years (Lau et al., 2002). Therefore, avoiding tobacco smoke exposure is effective and
important in the primary prevention of allergies.
Exposure to indoor allergens
Views conflict of whether early exposure to indoor allergens affects the development of
allergies (Chen et al., 2008).  Indoor exposure to cat or house-dust mites has elevated
risk for sensitization under the age of 3 (Wahn et al., 1997) but has no effect on asthma
up to age 7 (Lau et al., 2002). In high-risk children, avoidance of exposure to house-
dust mites from birth fails to prevent asthma, eczema, or atopy at age 5 (Marks et al.,
2006). Keeping indoor pets may protect from asthma and atopy (Rönmark et al., 2003;
von Hertzen et al., 2006). Keeping dogs indoor during early life associates with less
wheeze later in life in children with non-asthmatic parents (Remes et al., 2001), and
multiple ( 2) indoor dogs or cats during the first year of life reduces risk for
sensitization later in childhood (Ownby et al., 2002). The risk for allergy related to pet-
keeping varies with heredity, wider environmental exposure to pet allergens, and type
of exposure (Svanes et al., 2003).
Benefits of pet-keeping may be mediated by the increased exposure to microbes and
endotoxin (von Mutius and Schmid, 2006). The protective effect of endotoxin on
sensitization depends on a certain gene polymorphism (Simpson et al., 2006). Early cat
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exposure causes increased eczema in those with a weakened skin barrier due to loss of
function in the gene coding filaggrin (Bisgaard et al., 2008). That heavy allergen
exposure induces tolerance by stimulating more IgG and IgG4 antibodies than IgE
antibodies (Platts-Mills et al., 2001) may explain the controversy over allergen
avoidance in the primary prevention of allergies. Removing pets from the home or
reducing daily house-dust-mite exposure is unlikely to prevent allergies from
developing at population level (Remes et al., 2001; Corver et al., 2006; von Mutius and
Schmid, 2006).
Nutrition
The role of breast-feeding in the emergence of allergies is controversial and depends on
heredity and mothers’ allergies. Meta-analyses have indicated that exclusive breast-
feeding for 3 months reduces risk for rhinitis and asthma, especially in children with
family history of atopy (Eigenmann, 2004). Early signs of allergic diseases may prolong
exclusive breast-feeding, which may mask its protective effect or even show a reversed
causation between breast-feeding and allergies (Lowe et al., 2006). When the onset of
allergic symptoms was also considered, breast-feeding for the first 4 months of life
reduced risk for asthma, especially in children without an allergic heredity in Sweden
(Kull et al., 2004).  In a large cohort of Finnish children, exclusive breast-feeding for 3
months protected infants with atopic heredity from sensitization and allergic rhinitis at
age 4 years, whereas in children without atopic heredity the risk for symptomatic
allergy increased (Siltanen et al., 2003). Exclusive breast-feeding 4 months was
beneficial to lung function at school-age among Arizona children, but was associated
with decreased airflows among those whose mothers had asthma (Guilbert et al., 2007).
In an un-selected Finnish birth cohort, prolonged exclusive breast-feeding for more than
9 months was associated with increased incidence of eczema at the age of 20 (Pesonen
et al., 2006).
Secretory IgA, immune cells, cytokines, galacto-oligosaccharides, and fatty acids in
breast milk modify early immune responses (Brandtzaeg, 2002; Wijga et al., 2006).
Low contents of regulatory cytokines or secretory IgA in breast milk have been
associated with increased risk for allergic diseases and sensitization (Savilahti et al.,
1991, Savilahti et al., 2005; Saarinen et al., 1999b; Oddy et al., 2003), and high content
of -3 long-chain fatty acids have been associated with reduced risk for symptomatic
allergies (Wijga et al., 2006). Breast milk provides numerous health benefits to
newborn infants (Brandtzaeg, 2003), among them protection against allergies when fed
exclusively for the first 4 to 6 months regardless of atopic heredity (Høst et al., 2008).
In primary prevention of allergies, prolonged exclusive breast feeding in high-risk
families is, however, is unlikely to be beneficial (Eigenmann, 2004).
Elimination diets during pregnancy have failed to prevent allergies. Such diets
during lactation may delay the onset of eczema, but the disease thereafter may be more
severe (Greer et al., 2008; Høst et al., 2008). In high-risk infants, however, when early
supplementary feeding is needed, use of hydrolyzed formula instead of regular adapted
cow’s milk may delay the appearance of allergies (Osborn and Sinn, 2006). Although
avoidance of solid foods or cow’s milk in the infant’s diet for the first 4 months may be
beneficial, delayed introduction of solid foods (>6 months of  age) is unlikely to be
beneficial (Greer et al., 2008; Høst et al., 2008). Unnecessary elimination of foods
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exposes infants to a lack of protective nutrients and delays development of tolerance to
food antigens (Kankaanpää et al., 1999; Arvola and Holmberg-Marttila, 1999). For
example, fish is rich in -3 polyunsaturated fatty acids, which are considered anti-
inflammatory. When the possibility of reverse causation between parental allergy or
child’s early symptoms and introduction of fish to the diet was considered, regular fish
consumption during the first year of life did protect against allergies and sensitization
(Kull et al., 2006).
Antibiotics and vaccination
Any use of antibiotics during the first months of life has been related to later
development of childhood atopy or wheezing (Alm et al., 2008; Johnson et al., 2005;
Marra et al., 2006). However, opposing evidence showing the lack of any effect of
antibiotics during the first year of life on later development of asthma suggests that
frequent antibiotic use is a marker of risk for being diagnosed with asthma (Celedon et
al., 2004). Evidence from large cross-sectional studies does not support childhood
vaccinations as playing any role in the allergy development. Tuberculin vaccine
containing bacterial antigens may even induce tolerance against allergens. Thus, refusal
of vaccination does not reduce the risk for allergies, but unnecessarily exposes the child
to serious infections (Grüber, 2005).
Westernization
Based on his epidemiological observations, Gerrard et al. postulated in 1976 that
“atopic disease is the price paid by some members of the white community… for their
relative freedom from diseases due to viruses, bacteria, and helminthes.” Allergies
affect especially the high-income Westernized countries with clean environments and
life-styles with little exposure to microbes (Wold, 1998; Weinmayr et al., 2007). In the
former socialist countries of Europe, atopy and allergic diseases in children were rare
but have increased because of progressive Westernization (von Mutius et al., 1998). In
2003, among 7- to 16-year-old school children in two regions of Finnish and Russian
Karelia, geographically related but with fundamental differences in living
environments, sensitization, eczema, and allergic rhinitis, occurred 3-, 6-, and 14-fold
more frequently in Finland (von Hertzen et al., 2006; Pekkarinen et al., 2007). In
Russian Karelia, less allergic and less sensitized people are exposed daily to a greater
diversity of microbes than are their Finnish counterparts (von Hertzen et al., 2007).
Farming environment and anthroposophic lifestyle
Living on a farm in childhood has protected Finnish 18- to 24-year-old university
students from allergic rhino-conjunctivitis and asthma, but a rural non-farm
environment compared to an urban milieu was not protective (Kilpeläinen et al., 2000).
In 2001, among 6- to 13-year-old Finnish children living currently in a rural
environment, asthma and sensitization were less common in farmers’ than in non-
farmers’ children (Remes et al., 2005). In a large European study, growing up on a farm
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or leading an anthroposophic life-style protected against allergies and sensitization
(Alfvén et al., 2006).
An anthroposophic life-style is characterized by restricted antibiotic use and less
childhood vaccination, and by consumption of fermented foods plentiful in lactic acid
bacteria (Alm et al., 1999; Alfvén et al., 2006).
Farmers’ children are exposed to large quantities of microbes. Exposure to
endotoxin, which is a cell-wall structure in Gram-negative bacteria, is indicative of
wider bacterial contact. Increased endotoxin exposure has been associated with living
on a farm and with reduced risk for atopy and for asthma (Gereda et al., 2000; von
Mutius et al., 2000; Braun-Fahrländer et al., 2002)  The protective effect of livestock
against allergy is also believed to be mediated through increased exposure to endotoxin
(Remes et al., 2003; Riedler et al., 2001). Consumption of non-pasteurized farm-milk
may also mediate the protective effect of farm life against atopy (Perkin and Strachan,
2006). Polymorphism in the TLR2 gene confers protection against atopy in farmers’
children (Lauener et al., 2002; Eder et al., 2004), and a recently discovered
polymorphism in an asthma candidate gene modifies the effect of livestock contact on
the development allergic symptoms (Bruce et al., 2008).
Childhood infections
In 1989, Strachan observed a diminished risk for hay fever with rising birth order and
hypothesized that the allergy epidemic is a consequence of reduced exposure to
childhood infections. Termed the “hygiene hypothesis” (Strachan, 1989), it is supported
by the finding of fewer allergic diseases and sensitization among children exposed to
infections in big families or at day-care in very early life (Krämer et al., 1999; Ball et
al., 2000; Kilpi et al., 2002; Turner et al., 2005). Controversially, in large birth cohorts,
plentiful respiratory infections later in childhood are associated with more wheeze,
seasonal rhinitis (Harris et al., 2007), and eczema (Paunio et al., 2006). Childhood
infections may thus be one cause of the atopic phenotype, characterized by delayed
immune maturation and a poor defense against infections (Wjst, 2004).
Heavy exposure to orofecal and food-borne microbes have been protective against
respiratory allergies (Matricardi et al., 2000), but genetic factors seem to modulate the
effect (McIntire et al., 2003). Wild-type measles associates with less atopy in African
children (Shaheen et al., 1996), but not in Finnish children (Paunio et al., 2000).
Chronic helminth infections are associated inversely with atopy in developing
countries (Yazdanbakhsh et al., 2002). They seem to stimulate anti-inflammatory
regulatory cytokines and thus suppress atopy (van den Biggelaar et al., 2000). This is
supported by treatment studies showing that eradication of chronic helminth infections
leads to increased atopic reactivity, i.e., skin prick test reactivity to house dust mites
(van den Biggelaar et al., 2004). In developed countries, no inverse association has been
observable between helminth infections and atopy (Karadag et al., 2006).
It seems that more than mild viral infections or improved domestic hygiene, it is
fundamental changes in lifestyle, leading to the disappearance of serious infections and
reducing exposure to microbes in our daily environment, which may lie behind the
allergy epidemics (Wold, 1998).
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Gut microbiota in general
The gut microbiota, with up to 100 trillion microbes, provides the greatest microbial
exposure throughout life. Microbes occupy all available habitats and niches from the
intestinal lumen to crypts and epithelial-cell surfaces with an increasing gradient from
stomach to colon (Mackie et al., 1999; Ley et al., 2006). The gut microbiota undergo
huge metabolic activity. Fermentation of their main substrates— dietary carbohydrates
(starches, dietary fiber, unabsorbed sugars, and sugar alcohols)— produces short-chain
fatty acids (acetate, propionate, and butyrate), carbon dioxide, and molecular hydrogen.
Organic acids such as lactic acid are important intermediates of bacterial fermentation
(Blaut and Clavel, 2007).
Culturing fecal samples reveals only a diminutive fraction of the estimated whole
microbiota (Ley et al., 2006; Flint et al., 2007). To properly understand the microbial
diversity requires modern culture-independent methods based on sequence comparison
of nucleic acids (DNA or RNA) (Mackie et al., 1999). Using 16S rRNA oligonucleotid
probes, cutoffs of 95% and 98% similarity are applied to define genus and species,
respectively, and unique sequence types to identify strains (Bäckhed et al., 2005).
The sterile newborn gut is gradually colonized by environmental bacteria, which
outnumber human cells in the whole body within weeks (Mackie et al., 1999; Favier et
al., 2002). Facultative anaerobes (enterobacteria, coliforms, lactobacilli and
streptococci) are first detected in the feces, followed by obligate anaerobes
(bifidobacteria, clostridia and Bacteroides) in a week, and by other strictly obligate
anaerobes after weaning, to accomplish a highly diversified flora (Harmsen et al., 2000;
Adlerberth et al., 2006; Flint et al., 2007). Only a few highly dominant phylogenetic
groups appear in the gut microbiota, with Bifidobacterium predominance in infants.
After the first year of life, the commensal flora with >500 predominantly anaerobe
species becomes relatively stable. It fluctuates in response to antimicrobial treatment
and— to a lesser extent— to dietary changes (Salminen et al., 2005; Noverr and
Huffnagle, 2004; Eckburg et al., 2005). The host genotype also influences the
composition of gut microbiota, in view of the more similar microflora between twins
than between marital couples having a similar daily environment (Forchielli and
Walker, 2005; Walker et al., 2006).
Mode of delivery and the type of feeding influence the initial colonization
(Adlerberth et al., 1991, 2006). Term, vaginally born, and exclusively breast-fed infants
acquire the most beneficial microbiota with few C. difficile and E.coli and numerous
bifidobacteria and lactobacilli (Penders et al., 2006). Bacteria in the mother’s colon are
the strongest determinant of the early colonization after vaginal delivery (Salminen et
al., 2005). Cesarean section delays fecal colonization of bifidobacteria, lactobacilli, and
Bacteroides (Adlerberth et al., 2006; Grönlund et al., 1999) and may affect composition
of the gut microbiota up to school-age (Salminen et al., 2004b). Human milk
oligosaccharides promote the growth and activity of bifidobacteria and lactobacilli
(Harmsen et al., 2000; Tuohy et al., 2005), which more abundantly colonize breast-fed
than formula-fed infants (Brunser et al., 2006).
In Westernized environments, staphylococci have replaced traditional bacteria such
as Bacteroides in the gut flora. Recovery of skin-origin staphylococci in the feces
indicates the paucity of gut microbial species and late diversification of the gut
microbiota associates with the Westernized life-style (Adlerberth et al., 2006). In poor,
unhygienic environments, the gut flora has a high diversity and a high turnover rate
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(Adlerberth et al., 1998). Such conditions, related to decreased risk for allergies,
provide continuous exposure to extensive array of bacteria in drinking water and in the
soil and constantly stimulate the immune system (von Hertzen et al., 2007).
Gut microbiota in allergies
Gut microbiota are essential for the development of the entire immune system and for
the maintenance of immune homeostasis (Cebra, 1999; Kelly et al., 2005). Studies on
animals have revealed that gut microbiota are essential for the diversification of the
antibody repertoire (Lanning et al., 2000), and that without gut microbiota, oral
tolerance— peripheral immunological unresponsiveness to orally administered
antigens— fails to develop (Sudo et al., 1997). However, in germ-free animal models,
the under-developed immune function is rapidly restored after introduction of even a
single bacterial strain (Cebra, 1999).
Gut microflora of allergic and healthy infants differ. In two countries with differing
prevalences of allergy (low in Estonia, high in Sweden), allergic infants, when
compared to healthy infants, were less frequently colonized with lactobacilli and
Bacteroides, and more often with aerobic bacteria such as skin staphylococci and
coliforms (Björkstén et al., 1999). The aberrant gut microflora in allergies has been
confirmed by several studies (Sepp et al., 2005; Kirjavainen et al., 2001; Watanabe et
al., 2003), although similar gut microbiota have been observed between healthy and
allergic infants in European cohorts (Kendler et al., 2006). Prospectively studied, early
fecal samples of infants who go on to develop allergies compared to those who remain
healthy grow less enterococci, bifidobacteria, and Bacteroides, and more clostridia and
staphylococci (Björkstén et al., 2001). In a Finnish study of genetically allergy-prone
infants, early gut microbiota also differed between those who went on to develop
sensitization and those non-sensitized by age one (Kalliomäki et al., 2001a). A recent
prospective European multicenter study of over 300 infants found no association
between time of acquisition of any particular bacteria assessed by cultivation and
development of eczema or food sensitization. However, the incidence of eczema and
use of antibiotics in early life varied noticeably between centers (Adlerberth et al.,
2007).
In conclusion, early microflora, which are affected by the host, by environmental
microbial pressure, and by early events, seem to be related to development of allergies.
Several studies indicate that the gut microbiota of infants who go on to develop allergy
differ from the microbiota of those who remain non-allergic.
2.1.6 Current recommendations for allergy prevention
The World Allergy Organization Guidelines for Prevention of Allergy and Allergic
Asthma defines prevention of immunological sensitization in the form of specific-IgE
antibodies as primary, and prevention of symptomatic allergic diseases following
sensitization as secondary. It recommends avoidance of exposure to tobacco smoke
during pregnancy and in childhood for all infants, and exposure to inhalant allergens for
high-risk children. Avoidance diets for pregnant or lactating mothers are not
recommended, however (Asher et al., 2004). The European Academy of Allergy and
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Clinical Immunology Pediatric Expert Group of Dietary Prevention of Allergic
Diseases concludes that breast-feeding is beneficial irrespective of atopic heredity. For
high-risk infants it recommends exclusive breast-feeding for at least 4 to 6 months and
hypoallergenic formulas for the first 4 months if breast milk is insufficient. No dietary
restrictions are recommended after the age of 4 to 6 months (Høst et al., 2008). Because
avoidance has failed to prevent allergies effectively, new strategies are sought to
establish tolerance. Among these are immune modulation with microbial products,
including bacterial extracts, mycobacteria, lipopolysaccharides, and probiotics
(Matricardi et al., 2003).
2.2 Probiotics
2.2.1 Definition
Probiotics are “live microorganisms, which when consumed in adequate amounts,
confer a health benefit on the host” (FAO/WHO, 2002). They are a heterogeneous
group of bacteria with specific biological activities. After being applied in veterinary
medicine for decades, probiotics were adapted to human dietary and medical needs in
the 1990s. Since then, a rapid increase has occurred in probiotic research as well as in
the consumption of commercially available probiotic products (Salminen et al., 2002;
Saxelin, 2008).
Lactobacilli, bifidobacteria, and streptococci are the probiotics most commonly
selected from among human microbiota or dairy-product starters. Lactobacilli,
bifidobacteria, and propionibacteria belong to the lactic acid bacteria group, which
comprise fermentative Gram-positive bacteria and produce lactic acid as their main
fermentation product. The genus Lactobacillus, with over 80 known species, belongs to
the phylum Firmicutes, with a low DNA cytosine-guanine oligonucleotide (GC)
content. Lactobacilli are naturally present in human and animal intestines and in
fermented vegetables or dairy products. L. rhamnosus GG, which was isolated from
human feces by Gorbach and Goldin, is the most studied probiotic (Salminen et al.,
2005). The high GC-content genera Bifidobacterium and Propionibacterium belong to
the phylum Actinobacteri (Ben Amor et al., 2007). Bifidobacteria are natural residents
of the human intestine, but propionibacteria occur naturally in dairy products and
traditionally serve as cheese-starters. Propionibacteria exhibit many beneficial
properties in the human gut, among them their bifidogenic effect and inhibition of
undesirable colonization. Propionibacteria as probiotics have been used in
combinations, but little is known of their immune-modulating properties when used




To be effective, probiotic bacteria must survive the acidic conditions of the stomach and
must be resistant to bile salts and digestive enzymes (Salminen et al., 2005). Probiotic
bacteria actively metabolize and synthesize proteins in order to adapt to the
environment (Mater and Corthier, 2004). In animal models, they demonstrate protein
synthesis during gastrointestinal transit (Saxelin et al., 2005). The requirement of
viability has been challenged, however, since even fragments of probiotics or heat-
killed bacteria have stimulated immune responses. In mice, heat-killed L. rhamnosus
GG has led to increased antigen-specific systemic IgG and mucosal IgA in response to
ovalbumin immunization (He et al., 2005). Nevertheless, live bacteria have stimulated
higher levels of pro- and anti-inflammatory cytokines than have heat-killed preparations
(Cross et al., 2004).
Adherence of probiotic bacteria to intestinal cells may be vital to their colonization
and to their clinical effects, because strains that adhere stay longer on the intestinal
epithelium and maintain contact with immune cells (Salminen et al., 2005).  For
example, in diarrhea, although one non-adhering lactobacillus strain, L. bulgaricus, is
ineffective, the adhering L. rhamnosus GG strain is effective (Saavedra et al., 1994).
Lactobacillus species share a limited number of common genes which mediate their
attachment to mucin and to human intestinal cells (Saxelin et al., 2005). Because the
intestinal environment affects probiotic gene expression, strains adhering similarly in
vitro may adhere differently in vivo. That orally administered non-pathogenic E. coli
O83 attaches to epithelial cells and colonizes better in breast-fed than in formula-fed
infants indicates that feeding affects bacterial attachment (Lodinova-Zadnikova et al.,
1991). Although culturing probiotic strains in the feces indicates their survival during
intestinal transit, little else may be concluded regarding their adherence by cultivation
studies (Alander et al., 1999).
Colonization
Colonization of probiotics in the gut is temporary and may depend on prior
antimicrobial therapy (Agarwal et al., 2003; Bennet et al., 1992).  Probiotic bacteria are
detectable in the feces for weeks to months after administration, but no permanent
changes in overall colonization patterns occur. Although the early months of life are
critical to the formation of the commensal flora, even neonatal administration of
probiotics fails to ensure permanent colonization (Gueimonde et al., 2006). L.
rhamnosus GG given to pregnant mothers was discovered in the feces of vaginally born




The effects of probiotics are strain-specific. In vitro, Lactobacillus or Bifidobacterium
species modulate cytokine expression of dendritic cells differently, and they may act
synergistically or inhibit other species of the same genus in mixtures (Christensen et al.,
2002; Maassen et al., 2000; Vinderola et al., 2002). Moreover, Lactobacillus strains
with similar in vitro survival, growth, and adherence profiles also induce immune
responses differently in vivo (Reid, 2005); the in vivo  functionality of different strains
may therefore not be deduced from in vitro  experiments (Flinterman et al., 2007;
Vinderola et al., 2004).
Probiotic products are recommended to be administered in combinations, as these
may be functionally more efficient than individual strains (Rolfe, 2000). Introducing
several strains together enhances their probability to colonize intestinal niches, and the
strains may complement each other’s health effects. In children receiving antibiotic
therapy, probiotic combinations of several Lactobacillus and Bifidobacterium strains
have more effectively prevented antibiotic-induced dysbiosis, i.e., detrimental
metabolic effects and clinical gastrointestinal symptoms, than have single strains
(Timmerman et al., 2004). L. rhamnosus GG, L. rhamnosus LC705, P. freudenreichii
ssp. shermanii  JS, and Bifidobacterium breve Bb99 adhere and inhibit pathogen
adhesion more efficiently when administered together in combination than individually
(Collado et al., 2006, 2007). L. rhamnosus LC705 and P. freudenreichii ssp. shermanii
have also synergistically inhibited the growth of yeasts and molds in vitro (Suomalainen
and Mäyrä-Mäkinen, 1999). In animal studies, mixtures of gut microbial species have
more effectively stimulated the immune system than have single strains (Lanning et al.,
2000; Kelly et al., 2005).
2.2.3 Mechanism of action
Metabolic activity
Fermentation products of lactic acid bacteria (acetate, propionate, butyrate) provide
energy for the gastrointestinal mucosa and in distant organs (Tuohy et al., 2005).
Probiotic bacteria contribute to host energy resources also by influencing host genes
involved in nutrient uptake and energy metabolism (Kelleher et al., 2002; Walker et al.,
2006). The metabolism of lactic acid bacteria lowers gastrointestinal pH, which
improves degradation of food antigens to less allergenic fragments (Untersmayr et al.,
2005). Low pH, together with lactic acid and other bactericide metabolites, inhibits the
adhesion, growth, and activity of pathogenic bacteria (De Keersmaecker et al., 2006).
Barrier function
Similarly to commensal bacteria, probiotics provide a protective barrier and offer
colonization resistance against pathogens by competing for nutrients and binding sites
(Saxelin et al., 2005). Microbiota form mucus and biofilms, and influence expression of
host genes involved in the maintenance of the barrier function, thus impeding passage
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of food antigens and sensitization against them (Walker, 2008; Saxelin et al., 2005).
Reinforcement of the barrier function of the relatively permeable gut epithelium of
neonates by probiotics may be beneficial, because intestinal permeability plays a role in
the pathogenesis of food allergy and eczema (Arvola et al., 2004). Probiotic bacteria in
vitro strengthen epithelial-cell tight junctions (Saxelin et al., 2005). In children
suffering from eczema, L. rhamnosus and L. reuteri together have reversed the
increased gut permeability (Rosenfeldt et al., 2004), and in cow’s milk allergy and
eczema, L. rhamnosus GG, but not the combination of four probiotic strains, has
reduced intestinal permeability (Kuitunen et al., 2007). In addition, in preterm infants,
bifidobacteria have reduced intestinal permeability (Stratiki et al., 2007).
Modulation of immune responses
T h 1 – t y p e   r e s p o n s e s
Probiotic bacteria induce pro- and anti-inflammatory responses through TLRs on the
dendritic cells which reside throughout the gut epithelium, and modulate immune
responses strain-specifically (Hart et al., 2004; Walker, 2008).  Peptidoglycans and
lipoteichoic acid in the lactobacilli cell wall are recognized by TLR2, and CpG-motifs
of bifidobacterial DNA are recognized by intracellular TLR9 (Cario et al., 2007;
Saxelin et al., 2005). Stimulated dendritic cells then orchestrate maturation of Th1, Th2,
and T regulatory cell responses (Medzhitov et al., 1997; Walker, 2008) (Figure 1). L.
casei shirota in mice induces Th1 type pro-inflammatory responses and attenuates Th2-
type cytokine secretion (Matsuzaki and Chin, 2000). A variety of Lactobacillus and
Bifidobacterium strains stimulated human peripheral mononuclear cells to produce pro-
inflammatory IL-6 and tumor necrosis factor-  (TNF- ) (Miettinen et al., 1996).
Lactobacillus strains induce secretion of TNF-  through TLR2 and the NF B-pathway
(Matsuguchi et al., 2003). L. rhamnosus GG and pathogenic Streptococcus pyogenes
both activate the NF B-pathway, but the pro-inflammatory response to L. rhamnosus
GG is much weaker than to Str. pyogenes (Miettinen et al., 2000; Veckman et al.,
2004).
In infants with atopic heredity, probiotics have stimulated the maturation of the
delayed Th1-type immunity (Prescott and Björkstén, 2007). In infants with eczema and
cow’s milk allergy, L. rhamnosus GG reverses their defective IFN-  secretion of
peripheral mononuclear cells (Pohjavuori et al., 2004), and clinical improvement of
eczema in infants using L. fermentum is associated with increased IFN-  responses
(Prescott et al., 2005). Probiotics may stimulate the maturation of the immune system
by inducing a weak physiological inflammation (Viljanen et al., 2005b), which is
similar to the inflammation maintained by the indigenous intestinal microbiota
(O'Farrelly, 1998; Viljanen et al., 2005a). In atopic eczema, L. rhamnosus GG elevated
circulating inflammatory markers such as proinflammatory IL-6 and C-reactive protein
(Viljanen et al., 2005b).
R e g u l a t o r y   T – c e l l   r e s p o n s e s
Selective probiotics induce IL-10-producing regulatory T cells in vitro by modulating
dendritic cell function through intercellular adhesion molecules (Smits et al., 2005). In
vitro, lactic acid bacteria including L. rhamnosus GG have stimulated human
mononuclear cells to produce IL-10 (Miettinen et al., 1996; Kopp et al., 2008a), and
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bifidobacteria (in a mixture of eight probiotic strains) have induced IL-10 secretion in
dendritic cells (Martino et al., 2008). In children suffering from eczema, L. rhamnosus
GG alone and in a mixture of four probiotic strains has raised serum IL-10 (Pessi et al.,
2000; Viljanen et al., 2005b). In healthy infants with atopic heredity, L. rhamnosus GG,
L. rhamnosus LC705, B. breve, and P. freudenreichii JS in combination induced a low-
grade inflammation characterized by elevation of serum C-reactive protein, IL-10 and a
pro-inflammatory response resembling those observable in helminth infections
(Marschan et al., 2008b).
H u m o r a l   r e s p o n s e s
The anti-allergic effect of L. rhamnosus GG has been suggested to be due to
reinforcement of an IgA-mediated defense. IgA on mucosal surfaces participates in
antigen elimination and maintenance of mucosal barrier function (Brandtzaeg, 2002).
Initiation of IgA production during the first weeks of life is highly dependant on the gut
microbiota (Harris et al., 2006), and several probiotic strains are capable of stimulating
IgA secretion (Cross, 2002). L. rhamnosus GG stimulates both circulating and secretory
IgA systems in allergic children (Viljanen et al., 2005a), and in healthy bottle-fed
(Rautava et al., 2006) or breast-fed infants (Rinne et al., 2005).
In acute rotavirus diarrhea, L. rhamnosus GG induces circulating rotavirus-specific
and non-specific IgA-secreting cells (Majamaa et al., 1995; Kaila et al., 1992). In
addition to IgA, certain probiotics have promoted both mucosal and systemic IgM and
IgG antibody responses to orally administered vaccines (Isolauri et al., 1995; Link-
Amster et al., 1994; He et al., 2000). In infants receiving fermented formula compared
to conventional formula for 4 months, intestinal poliovirus-specific IgA following
parenteral poliovirus vaccine increased concomitantly with fecal bifidobacteria (Mullie
et al., 2004). Lactobacillus strains have also modulated allergen- and vaccine-specific
immune responses (Taylor et al., 2006; West et al., 2008).
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Figure 1 Mechanisms of probiotic action. 1. Metabolize facilitation of food
degradation and bacteriosidic activity, 2. Competition with pathogens for
receptor binding sites and substrates, 3. Increase in barrier function, 4. Increase
in secretory and serum IgA, 5. Reinforcement of Th1 type immune responses, 6.
Increase in regulatory activity to suppress Th2 type allergic responses TLR, Toll-
like receptor, Th, T helper cell, Treg, regulatory T cell,  DC, dendritic cell, MF,















































2.2.4 Probiotics in general in pediatrics
Gastrointestinal disorders
The therapeutic effect of probiotics in children is well established in acute diarrhea. L.
rhamnosus GG, Str. thermophilus, L. reuteri, and L. acidophilus have shortened the
duration and reduced the severity of acute viral diarrhea (Kullen and Bettler, 2005;
Guandalini et al., 2000).  In severe infectious diarrhea, however, probiotics may lack
any effect (de Vrese and Marteau, 2007). The beneficial effect of probiotics in acute
diarrhea depends on the dose, timing (early), and strain, with L. rhamnosus GG alone or
in combinations showing the most consistent effect  (Szajewska and Mrukowicz, 2001;
van Niel et al., 2002; Canani et al., 2007). In the prevention of acute infectious diarrhea
(Sazawal et al., 2006) and antibiotic-associated diarrhea (Johnston et al., 2006;
Szajewska et al., 2006) in children, certain probiotic strains have been effective. L.
rhamnosus GG, L. reuteri, L. casei, or Str. thermophilus have successfully prevented
infectious diarrhea in children attending day-care (Weizman et al., 2005), in
hospitalized children (Saavedra et al., 1994), and in malnourished children with a high
burden of gastrointestinal infections (de Vrese and Marteau, 2007). In Finland, with its
low pressure of gastrointestinal infections, L. rhamnosus GG lacked any preventive
effect among children attending day-care (Hatakka et al., 2001).
Probiotics have showed promise in inflammatory bowel diseases and in necrotizing
enterocolitis in preterm infants. They have also been beneficial in infantile colic (Rolfe,
2000; Savino et al., 2007).
Respiratory tract infections
L. rhamnosus GG given in milk daily during 7 months reduced the number and severity
of respiratory infections and days of absence of Finnish children in day-care (Hatakka et
al., 2001). A mixture containing L. rhamnosus GG, L. rhamnosus LC705, B. breve, and
P. freudenreichii ssp. shermanii JS given for 6 months to otitis-prone Finnish children
lacked any preventive effect on the occurrence or  recurrence of acute ear infection but
led to increased nasopharyngeal carriage of Moraxella (Hatakka et al., 2007). A
formula containing Str. thermophilus plus B. lactis given to infants in day-care in the
United States for 7 months lowered the frequency of antibiotic use (Saavedra et al.,
2004). Formulas substituted with L. reuteri or B. lactis during 3 months lacked any
effect on respiratory illnesses in Israeli children in day-care (Weizman et al., 2005), and
L. acidophilus given to newborn Australian infants for 6 months lacked any effect on
respiratory infections, but its use was related to increased antibiotic use (Taylor et al.,
2007).
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Table 1. Probiotics in the treatment of eczema. SCORAD index: mild <25, moderate 25 to 50, severe >50 (SCORAD, 1993; Oranje et al.,











Intervention (daily amount of
probiotics  in cfus)
Duration
(weeks)




I  ?(2 to 16) mo




AI: LGG 5x108 /g of  HF




Yes 27 5 mo Mild (16) ?
AI: LGG 3x108/g of  HF






43 5 (1 to 13) y Moderate (38) 63
A: L. rhamnosus 20x1010 and L. reuteri






Yes 230 6 (1 to 12) mo Moderate (33) 59
AI:  LGG 10x109  in powder,
AII:LGG10x109, L. rhamnosus LC705
10x109, B.breve 4x108, P. freudenreichii






Yes 56 11 (6 to 18) mo Moderate (42) 71





Yes 42 4 (1 to 5) mo Mild (24) 38
AI: LGG 3x108 /g of HF
AII: L rhamnosus 3x108 /g of HF P:HF
12 No effect
Sistek et al. 2006
(New Zealand)
Yes 59 4 (1 to 10) y Moderate (30) 100
A: LGG and B lactis 2x1010  powder
P: Microcrystalline cellulose
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Yes 53 4 (1 to 55) mo Moderate (41) 38





Yes 103 7 (3 to 12) mo Mild (24) 55




Table 2. Randomized placebo-controlled clinical trials on prevention of childhood allergies by probiotics. Active treatment group (A),






























2, 4, 7 ? L. rhamnosus GG 1x1010 2 to 4
weeks before delivery, 6 months
after birth to lactating mothers,
otherwise to bottle-fed infants
Eczema
Sensitization
Reduced eczema at 2, 4, and
7 years

















































2 ? L. rhamnosus GG 5x109 twice daily
4 to 6 weeks before delivery, 6
months after birth to lactating





2.2.5 Probiotics in the treatment of allergies
Airway allergies
Probiotic effects in airway allergies have been studied in adult patients. L. rhamnosus
GG given to 18 Finnish birch-pollen-allergic adults for half a year, including the birch
pollen season, had no effect on symptoms or need for medication (Helin et al., 2002).
Asian studies on seasonal allergic rhinitis have shown reductions in total and pollen-
specific IgE with consumption of L. gasseri (Morita et al., 2006), and improvement of
symptoms with L. acidophilus (Ishida et al., 2005a), B. longum (Xiao et al., 2006), and
L. paracasei (Wang et al., 2004). Although yogurt containing L. acidophilus consumed
during one month lacked any effect on asthma symptoms or lung function in atopic
asthmatics, eosinophilia decreased, and IFN-  tended to increase (Wheeler et al., 1997).
The studies on probiotics in airway allergies have been small, and no convincing
evidence regarding any benefit exists, nor data on pediatric patients (Boyle and Tang,
2006).
Food allergy and eczema
L. rhamnosus GG in the treatment of eczema was first studied in 42 Finnish infants
referred to a hospital for suspected cow’s milk allergy in 1997 (Majamaa et al., 1997).
L. rhamnosus GG was given for one month to 11 breast-feeding mothers or directly to
15 infants receiving extensively hydrolyzed formula. In the control group, 16 infants
received only extensively hydrolyzed formula. All infants were treated with emollients
and topical corticosteroids, and cow’s milk was eliminated from their diets. In the final
analysis, 37 of 42 infants undergoing a positive cow’s milk challenge after the
intervention were included. Of these 37, the extent, intensity, and subjective symptoms
of eczema, as measured by the SCORAD index (Oranje et al., 2007; SCORAD, 1993),
improved significantly in the 13 formula-fed infants receiving L. rhamnosus GG and in
the 10 breast-fed infants whose mothers received L. rhamnosus GG. In the 14 control
infants, the SCORAD index remained unchanged. However, at 2 months the eczema
was comparably mild in both formula groups. Intestinal inflammation as measured by
fecal TNF-  and 1-antitrypsin was attenuated significantly in the probiotic formula
group compared to placebo (Majamaa and Isolauri, 1997). In another Finnish placebo-
controlled trial, involving 27 infants suffering from eczema during exclusive breast-
feeding, 9 were weaned onto extensively hydrolyzed formula, 9 infants onto the same
formula with added L. rhamnosus GG, and 9 infants received the same formula with
added B. lactis Bb12. After 2 months, in infants receiving the probiotic-containing
formulas, severity of eczema fell significantly, whereas the placebo group showed no
improvement; 6 months later, eczema had improved in all infants, with no difference
between study groups (Isolauri et al., 2000).
L. rhamnosus GG alone or in a mixture with L. rhamnosus LC705, B. breve, and P.
freudenreichii JS given daily during one month to 230 Finnish infants referred to
hospital for suspected cow’s milk allergy provided no additional benefit over an
elimination diet and intensive topical treatment. However, in the 136 IgE-sensitized
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infants, L. rhamnosus GG alone, but not the mixture, reduced severity of the eczema
(Viljanen et al., 2005c).  In two German studies, L. rhamnosus GG given for 3 months
lacked any beneficial effect over placebo on mild-to-moderate eczema in 102 infants 3
to 12 months old (55% sensitized) (Grüber et al., 2007) or when given for 2 months to
53  children aged 1 to 5 years, with 72% sensitized  (Fölster-Holst et al., 2006). In 42
Dutch infants aged 1 to 5 months, neither L. rhamnosus GG nor another L. rhamnosus
strain given for 3 months in hydrolyzed formula was superior to hydrolyzed formula
alone for eczema (Brouwer et al., 2006). For 59 infants in New Zealand, the
ameliorating effect of a 3-month supplementation of L. rhamnosus GG and B. lactis on
eczema was confined to food-sensitized infants (Sistek et al., 2006). L. rhamnosus and
L. reuteri administered in relatively large quantities for 6 weeks in a cross-over manner
to 43 Danish children (>60% sensitized) aged 1 to 13 years improved subjective
symptoms of eczema, but this improvement was not shown in objective clinical
symptom scores (Rosenfeldt et al., 2003). L. fermentum given during 2 months to 53
Australian 6- to 18-month-old infants, 71% of whom were sensitized, ameliorated their
moderate to severe eczema (Weston et al., 2005) .
A meta-analysis performed on four treatment trials concludes that probiotics are
unlikely to be beneficial in the treatment of eczema (Lee et al., 2008). However,
differences in probiotic preparations, in host genetics, and in environmental factors such
as environmental microbial burden and diet may explain the varied results and make
meta-analysis difficult to perform (Prescott and Björkstén, 2007).  Table 1 summarizes
randomized clinical trials on treatment of eczema.
2.2.6 Probiotics in the prevention of allergic diseases
In the first placebo-controlled randomized trial to prevent allergies in 132 genetically
high-risk infants, L. rhamnosus GG was given first to pregnant mothers and thereafter
to the lactating mothers or directly to non-breastfed babies during the 6 months after
birth (Kalliomäki et al., 2001b). At the age of 2 years, incidence of eczema halved in
the L. rhamnosus GG group (23%) compared to the placebo group (46%) without any
effect on sensitization against milk, egg, cat, or house dust mite as measured by serum
antigen-specific IgE or against a panel of common food, pollen, and animal antigens in
skin prick tests (18% vs. 14%). Although the beneficial effect on eczema was sustained
at the 4- and 7-year follow-ups, neither respiratory allergies nor sensitization was
reduced in the L. rhamnosus GG group (Kalliomäki et al., 2001b, 2003, 2007).
Recently, L. rhamnosus GG given to 105 pregnant mothers of high-risk infants for 4 to
6 weeks before delivery and to their infants during 6 months after birth compared to
placebo neither reduced the incidence of eczema (28% vs. 27%) nor altered
sensitization rates but was associated with an increased rate of recurrent wheezing
episodes (26% vs. 9%) (Kopp et al., 2008b).
L. acidophilus, not given during pregnancy but only to newborn infants of allergic
mothers from age <48 hours to 6 months, failed to prevent allergies compared to
placebo in the 12-month follow-up. Instead, the probiotic compared to placebo
significantly elevated risk for IgE-associated eczema (26% vs. 14%) and sensitization
against egg, cow’s milk, peanut, house-dust mite, cat, grass, or  mold as measured by
skin prick tests (40% vs. 24%). Fecal colonization of bifidobacteria and coliforms
assessed by a cultivation technique at ages one and 6 months did not significantly differ
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between the study groups, but lactobacilli were more frequently detected in the
probiotic than in the placebo group at one (23% vs. 13%) and 6 months (22% vs. 36%)
(Taylor et al., 2007). In a Swedish study, L. reuteri or placebo was given daily to
pregnant mothers of high-risk families from 36 weeks of gestation until delivery and to
their babies from birth until 12 months of age (Abrahamsson et al., 2007). In the 188
infants completing the 2-year follow-up, the cumulative incidence of eczema was 36%
in probiotic and 34% in the placebo group, and of atopic (IgE-associated) eczema was
17% vs. 28%, respectively. During the second year of life, atopic eczema was less
common in the L. reuteri (8%) than in the placebo group (20%). The cumulative
incidence of sensitization as measured by serum antigen-specific IgE against egg white
and cow’s milk or in a skin prick test against egg, milk, cat, birch, or timothy tended to
be lower in the probiotic group (18% vs. 29%). The protective effect of L. reuteri was
more pronounced in infants whose mothers were allergic; prenatal probiotic treatment
of pregnant mothers was therefore considered noteworthy.
One retrospective observation concerns non-pathogenic E. coli, administered to 150
term and 77 pre-term infants in order to prevent colonization by pathogens and to
stimulate immunity. Twenty years later, the infants colonized with the non-pathogenic
E. coli compared to time-matched controls had fewer atopic diseases (Lodinova-




The prebiotic concept was launched in 1995 by Gibson and Roberfroid. Prebiotics
denote non-digestible, selectively fermented carbohydrate food ingredients beneficial to
the host through stimulating the growth or activity of beneficial bacteria in the gut
(Boehm and Stahl, 2007; Gibson and Roberfroid, 1995). Inulin is a naturally appearing
prebiotic in vegetables; thus an adult diet including vegetables contains the
recommended daily dose of prebiotics to maintain a balanced microflora. Fructo-
oligosaccharides, which are among the most studied prebiotics along with inulin, are
derived from natural sources through hydrolysis or manufactured enzymatically. Both
inulin and fructo-oligosaccharides are polymers of D-fructose (Tuohy et al., 2005).
Prebiotic effects depend on solubility, distribution, and branching and length of the
chains (Rossi et al., 2005).
Human milk has been known for decades to promote bifidobacteria in the gut
microflora of breast-fed infants. A carbohydrate assumed to be responsible for the
bifidogenic effect was termed the “bifidus factor,” which— when administered to bottle-
fed infants— made their stools similar to those of breast-fed infants (Salmi and
Huuhtanen, 1957). In human milk are plentiful galacto-oligosaccharides (7 to 12 g/L),
which are today known to support the growth of bifidobacteria and beneficially modify
stool consistency. The composition of human milk oligosaccharides is not reproducible
by the food industry and is much more complex than the composition of bovine
oligosaccharides. However, human and bovine milk oligosaccharides share an
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important structure— -glycosidically bound galactose— which protects the molecule
against digestion in the small intestine (Boehm and Stahl, 2007).
2.3.2 Mechanism of action
Prebiotics are fermented by commensal bacteria, mainly by bifidobacteria, in the colon.
More than direct immunological effects, prebiotics cause their effects through the
metabolism of the bacteria they promote. The major products of prebiotic metabolism
are short-chain fatty acids (acetate, propionate, butyrate) which may be anti-
inflammatory (Tuohy et al., 2005). Prebiotic fermentation results in increased
hydrogen, carbon dioxide, and bacterial cell-mass (Cummings et al., 2001). In bottle-
fed infants, prebiotics facilitate the initial colonization by bifidobacteria (Haarman and
Knol, 2005; Moro et al., 2002) and result in a fermentation profile similar to that of
breast-fed infants: increased short-chain fatty acids and lactic acid accompanied by
lowered pH (Knol et al., 2005). In bottle-fed infants receiving galacto- and fructo-
oligosaccharides, fecal IgA tends to rise, which, however, fails to reach the level of
breast-fed infants (Bakker-Zierikzee et al., 2006). Stimulation of circulating and
secretory IgA systems have also been reported with prebiotics (Bakker-Zierikzee et al.,
2006).
2.3.3 Prebiotics in allergies
In the treatment of eczema, prebiotics were effective in a French study comparing
prebiotics and synbiotics, but the significance of either treatment is difficult to evaluate
in the absence of a placebo group (Passeron et al., 2006). A hydrolyzed formula
containing fructo- and galacto-oligosaccharides 0.8g/100ml in the proportion 9:1, or
hydrolyzed formula without prebiotics was given to 206 term infants with familial risk
for atopy. The infants started to receive bottle-feeds during the first 2 weeks of life. At 6
months, infants receiving prebiotics had less eczema (10% vs. 23%) (Moro et al., 2006)
and had fewer infectious episodes than did infants receiving hydrolyzed formula alone
(Arslanoglu et al., 2007).
2.4 Synbiotics
Synbiotics combine efficacious probiotic strains with prebiotics to enhance the in vivo
activity of the introduced probiotics and to stimulate beneficial microbial populations in
the commensal flora (Collins and Gibson, 1999; Tuohy et al., 2005). A synbiotic
combining L. casei with dextran prevented development of eczema in mice and showed
beneficial immunological effects in adult human patients suffering from pollen-induced
rhinitis (Ogawa et al., 2006). In a non-placebo-controlled trial, a synbiotic containing L.
rhamnosus Lcr35 plus prebiotics was not superior to the prebiotic alone in the treatment
of eczema (Passeron et al., 2006).
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2.5 Safety and regulations
Historical data support the safety of Lactobacillus and Bifidobacterium, which are
natural residents of the human gut (Adams and Marteau, 1995; Reid, 2005). The major
theoretical safety concerns of probiotic organisms are occurrence of bacteremia or
endocarditis, transfer of antibiotic resistance, and detrimental metabolic effects such as
production of D-lactate (Marteau, 2002; Snydman, 2008). As natural members of the
indigenous gut flora, lactobacilli and bifidobacteria may cause opportunistic infections
in immunocompromised patients. Although probiotic bacteria are not easily
translocated in healthy subjects, Lactobacillus, Leuconostoc, Pediococcus, and
Enterococcus have been isolated from infection sites (Liong, 2008). Lactobacillus
bacteremia or Saccharomyces boulardii fungemia may occur in elderly or critically ill
patients with structural heart defects or indwelling catheters or in patients with short-
bowel syndrome (Agostoni et al., 2004; Reid, 2005; Snydman, 2008). Two cases of L.
rhamnosus GG septicemia have been associated with the probiotic given to critically ill
children after surgery to cure broad-spectrum antibiotic-induced diarrhea (Land et al.,
2005). L. rhamnosus GG has been safe in various populations including neonates,
critically ill children, undernourished children, pregnant women, and
immunocompromised HIV-infected adults (Salminen et al., 2004a; Kullen and Bettler,
2005; Snydman, 2008). No Lactobacillus sepsis has occurred in the wealth of
randomized clinical trials (Hammerman et al., 2006), nor has increased consumption of
L. rhamnosus GG, L. acidophilus, or L. paracasei augmented septicemias in
population-based studies (Salminen et al., 2002;  Sullivan and Nord, 2006).
Natural antibiotic resistance of lactic acid bacteria to tetracycline, erythromycin, and
chloramphenicol is encoded in antibiotic-resistance genes of plasmids, the transfer of
which is rare (Snydman, 2008). The intrinsic vancomycin resistance of lactobacilli is
not mediated by plasmids and therefore not horizontally transferable (Reid, 2005).
However, lactic acid bacteria residing in human intestine that is regularly exposed to
antibiotics may acquire transferable antibiotic resistance (Mathur and Singh, 2005).
Many lactobacilli and bifidobacteria are naturally susceptible to amoxicillin, which
should be taken into account whenever it is used to prevent antibiotic-associated
diarrhea (Charteris et al., 1998). Bifidobacteria are naturally resistant to gentamicin,
sulfamethoxazole, and polymyxin B. That few Bifidobacterium strains have been
tetracycline-resistant warrants safety evaluation when selecting bifidobacteria for
probiotic use (Masco et al., 2006). Although no evidence exists of transferred antibiotic
resistance associated with probiotic use, careful post-marketing surveillance is
warranted (Klein et al., 2000).
Probiotics should be selected from strains having neither detrimental metabolic
effects nor production of D-lactate or toxins, nor deconjugation of bile salts or
hemolytic activity (Marteau, 2002). Neither L. rhamnosus GG nor L. rhamnosus LC705
produces systemic-acidosis creating D-lactate. L. rhamnosus GG is non-toxic, and there
is no lethal oral dose in mice (Snydman, 2008).
Some widely available probiotic products on the market in Europe have contained
traces of -lactoglobulin (Lee et al., 2007). Such contamination with -lactoglobulin
has caused life-threatening allergic reactions in cow’s milk-allergic individuals,
emphasizing the importance of using products from guaranteed high-quality
manufacturing processes (Moneret-Vautrin et al., 2006).
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L. rhamnosus GG has been well tolerated also in infants with low birth weight
(Agarwal et al., 2003). Healthy 3- to 24-month-old infants receiving a formula
containing S. thermophilus and B. lactis for more than half a year compared to infants
receiving regular formula grew normally, needed fewer antibiotics and less frequently
suffered from infantile colic (Saavedra et al., 2004). A synbiotic formula containing B.
longum and galacto-and fructo-oligosaccharides was safe and well tolerated in neonates
(Puccio et al., 2007). In a randomized trial with 40 infants receiving regular formula or
formula supplemented with Str. thermophilus and L. helveticus for the first 2 months of
life, normal growth ensued in both groups. (Langhendries et al., 1995; Agostoni et al.,
2004)
Prebiotics lack the traditional safety concerns of probiotics, because they are non-
viable and present in regular food. High doses of prebiotics (in adults >20 g/day) have
had laxative effects (Tuohy et al., 2005) and because of production of gases as their
fermentation products, unwanted flatulence is reported (Cummings et al., 2001). Inulin
and fructo-oligosaccharides have, in animal models, modified triglyceride and
cholesterol levels (Pereira and Gibson, 2002). Galacto-oligosaccharides and
polydextrose given to healthy neonates for 4 months were well tolerated, produced stool
characteristics similar to those of breast-fed infants, and resulted in normal growth
(Ziegler et al., 2007).
The exact strain of each probiotic should be identified by internationally accepted
methods (Reid, 2005), given a name in accordance with the International Code of
Nomenclature, and filed in an internationally recognized culture registry (FAO/WHO,
2002). Probiotics are regulated mainly in the context of food additives, the health claims
of which are more strictly regulated in the European Union than in the United States. In
the European Union, probiotics are regulated within the context of the Novel Food
Regulation EU 258/97. The European Food Safety Authority (EFSA) has proposed a
Qualified Presumption of Safety status in food for Lactobacillus (including L.
rhamnosus), Bifidobacterium, and Propionibacterium (particularly P. freudenreichii
ssp. shermanii) species.  In the US, certain probiotic strains have gained FDA approval
as “Generally Regarded as Safe” (Liong, 2008). Any product marketed as for treatment
or prevention of a disease should be registered as a drug and manufactured under the
Good Manufacturing Practices standard (Reid, 2005).
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3. Aims of the study
Our main objective was to discover whether a probiotic combination administered to
pregnant mothers and to their newborn infants along with prebiotics during the 6
months after birth compared to placebo prevents childhood allergies from developing in
infants with a hereditary risk for allergy. We aimed at discovering:
The effect of probiotics and prebiotics on the cumulative incidence of allergic
diseases and sensitization at age 2 years
The long-term safety of probiotics and prebiotics and their impact on respiratory and
gastrointestinal infections during the first 2 years of life
The effect of probiotics and prebiotics on vaccine-induced IgG antibody responses
at 6 months against tetanus, diphtheria, and Haemophilus influenzae vaccines
Mucosal immune responses preceding the development of allergic diseases and
sensitization, and the effect of probiotics and prebiotics on them
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4. Material and methods
4.1 Study design
4.1.1 Participants
The randomized, double-blind, and placebo-controlled trial with two parallel groups
was carried out at the Skin and Allergy Hospital of Helsinki University Central Hospital
during the period November 2000 to March 2003. Pregnant mothers were recruited
from antenatal clinics and through advertisements in local newspapers in the Helsinki
suburban area with 900 000 inhabitants and with a birth rate of 13 000 per year.
Mothers were eligible if one or both parents of the unborn child had a history of
physician-diagnosed allergic disease (allergic rhinitis, eczema, or asthma), evaluated in
telephone interviews by trained personnel. Pre-term infants (  37 weeks of gestation)
and infants with a major malformation were excluded. From multiple births only the
first-born child was eligible (Figure 3).
Figure 2 Study design: Populations in Studies I-IV
4.1.2 Intervention
From 36 weeks of gestation, mothers in the probiotic group took one capsule containing
Lactobacillus rhamnosus GG (ATCC 53103) 5x109 colony-forming units (cfu), L.
rhamnosus LC705 (DSM 7061) 5x109 cfu, Bifidobacterium breve Bb99 (DSM 13692)
2x108 cfu, and Propionibacterium freudenreichii ssp. shermanii  JS (DSM 7076) 2x109
cfu twice daily. Selection of the strains was based on their availability and on current
knowledge as to the safety and efficacy of individual strains or combinations. The
supplier regularly checked the viability of the bacteria in the capsules, and the total
amount of 109 cfu viable bacteria throughout storage was guaranteed.
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Each newborn infant received one opened capsule containing the same probiotics
mixed with 20 drops of sugar syrup (22% glucose, 20% fructose, and 27% saccharose),
containing 0.8g of galacto-oligosaccharides of bovine origin in liquid form once daily
for 6 months after birth. In the placebo group, mothers and their infants took capsules
containing microcrystalline cellulose, and the infants received sugar syrup without
galacto-oligosaccharides, all scheduled exactly as in the probiotic group.
Figure 3 Study protocol. In the probiotic group, mothers received a mixture
of Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve
Bb99, and Propionibacterium freudenreichii ssp. shermanii  JS twice daily from
36 weeks of gestation up to the delivery. Their infants received the same mixture
of probiotics and galacto-oligosaccharides. In the placebo group, mothers and
their infants received capsules containing microcrystalline cellulose, and the
infants received sugar syrup.
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Parents received illustrated instructions to mix the probiotic powder with liquid
(water, breast milk, or formula) in a teaspoon and were instructed to feed the mixture
with a spoon. The products (supplied by Valio, Helsinki, Finland), which looked,
smelled, and tasted identical, were delivered in numbered packages directly to the
mothers for their use over a 4-week period, and for the infants’ use during the first 3
months. The rest was supplied at the 3-month visit. The packages containing the
capsules were stored frozen until opened, and then refrigerated. The parents were
instructed to bring the remaining products to the study visits, and not to feed other
probiotic preparations to the infants during the intervention. Compliance with the
treatment was evaluated at the 3- and 6-month visits by asking the amount of doses not
given and by counting the returned capsules. The mothers were encouraged to breast-
feed, but if breast-feeding was insufficient, we recommended normal adapted cow’s
milk-based formula. The use of hypo-allergenic formula was restricted to infants
allergic to cow’s milk.
4.1.3 Vaccination
Vaccinations were given according to the Finnish national vaccination schedule.
According to this schedule the infants received a DTwP vaccine (National Public
Health Institute, Helsinki, Finland) consisting of 19 flocculating units of purified
diphtheria toxoid, 5 flocculating units of purified tetanus toxoid, and 5 x 109 inactivated
Bordetella pertussis cells at ages 3, 4, and 5 months. At 4 months, they received a
Haemophilus influenzae type b (Hib) conjugate vaccine, consisting of 10 µg Hib
capsular polysaccharide polyribosylribitol phosphate (PRP) covalently conjugated to
tetanus toxoid (PRP-T) (Hiberix®; GlaxoSmithKline, Rixensart, Belgium), or to
Corynebacterium diphtheria toxin CRM197 (HbOC) (HibTITER®; Wyeth-Lederle,
Vaccines & Pediatrics, Philadelphia, PA, USA). During the study, the vaccine
distributed to well-baby clinics by the National Public Health Institute of Finland
changed from the HbOC to the PRP-T.
4.1.4 Study visits and questionnaires
Study visits occurred when the infants were 3, 6, and 24 months of age. The study
pediatrician, blinded to group assignment, recorded the infant’s history of symptoms
related to allergic diseases, and clinically examined the infants. We advised the parents
to contact the study nurses or the pediatrician in the event of adverse reactions during
the intervention or if their child exhibited symptoms related to allergies such as eczema,
urticaria, vomiting, excessive crying, wheeze, or persistent or exercise-induced cough
between the study visits. Infants with suspected allergies were clinically evaluated.
Parents were advised to bring the child’s primary health-care chart to the study visits for
recording vaccination dates and anthropometric measurements.
The parents completed non-validated questionnaires when their child was 3, 6, 12,
and 24 months old. The questionnaires covered the respective periods 0 to 3, 3 to 6, 6 to
12, and 12 to 24 months. The first questionnaire covered pregnancy, birth, neonatal
morbidity, feeding and feeding-related behaviors, and symptoms of infantile colic,
parental education, and household size. In all questionnaires we inquired about the
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number of infections and antibiotic courses, use of commercially available probiotic
products, symptoms of allergic diseases, attendance at day-care, parental smoking, and
household pets. The questionnaires were delivered by mail except the 3- to 6-month
questionnaire, which was provided in person at the 3-month visit. The questionnaires
were returned during the study visits (at 3, 6, and 24 months) or by mail (12 months)
(Figure 3).
4.1.5 Diagnostic criteria of allergic diseases
Food allergy was defined as an adverse reaction (urticaria, eczema, gastrointestinal
symptoms) in an open food challenge after improvement during a 2-week elimination
diet (Bruijnzeel-Koomen et al., 1995). Eczema was defined as an itchy skin condition
and 3 of the following symptoms: familial history of atopic disease, dry skin during
the last year, history of eczema, and visible eczema involving typical sites (Williams et
al., 1994). Severity Scoring of Atopic Dermatitis (SCORAD) was assessed at the study
visits (SCORAD, 1993). Asthma was defined as 2 physician-diagnosed wheezing
episodes, accompanied by persistent cough or exercise-induced symptoms (NAEP,
2002). Allergic rhinitis was defined as antigen-specific sensitization with a history of 2
symptoms of nasal discharge, blockage, sneeze/itch, recurrently during antigen contact
(ARIA, 1994). Children with any positive skin prick test or any serum antigen-specific
IgE >0.7 kU/l (Vanto et al., 1999) at 2 years were sensitized. Any allergic disease in a
sensitized infant was considered atopic (Johansson et al., 2004).
4.1.6 Diagnostic tests and laboratory analysis
Skin prick tests
Skin prick tests were performed at the 6-month and 24-month visits on the volar surface
of the forearm with separate sterile lancets (ALK-Abellò, Hørsholm, Denmark). We
used histamine dihydrochloride (10 mg/ml) as a positive control and the solvent
(glycerin) as the negative control (ALK-Abellò). The allergen extracts tested included
egg white (1000 I.C. /ml; Stallergenes, Antony, France) at age 6 months and egg white,
fish (1000 I.C. /ml; Stallergenes), cat, dog, birch, timothy (10 HEP; ALK-Abellò),
cow’s milk, and wheat grains (diluted in 0.9% sodium chloride) at 2 years. The wheal
size was calculated as the mean of the longest diameter and its orthogonal diameter at
15 minutes. A wheal sized 3mm greater than the negative control we considered
positive (EAACI, 1993).
Blood samples
A blood sample was drawn with parental permission at 6 months and at 2 years. Local
anesthetic cream (EMLA®, Astrazeneca, Södertälje, Sweden) was applied to the
puncture site prior to blood sampling. Centrifuged serum samples were stored at -40ºC.
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At 2 years, serum allergen-specific IgE antibody concentrations against cow’s milk,
egg white, birch, timothy, dog, and cat were measured by immunoassay
(ImmunoCAP® system, Pharmacia diagnostics, Uppsala, Sweden) with a detection
limit of 0.01 kU/L. A concentration of >0.7 kU/l was considered positive (Vanto et al.,
1999). Serum total IgE was measured by the same immunoassay with a detection limit
of 2 kU/l.
At 6 months, we measured serum toxin-neutralizing IgG antibodies against
diphtheria and tetanus by a double-antigen ELISA with a detection limit of 0.007 IU/ml
(Kristiansen et al., 1997). All samples drawn  14 days after the third DTwP dose were
eligible. We measured serum anti-capsular polysaccharide Hib IgG antibodies by
enzyme immunoassay with a detection limit of 0.3 µg/ml. Samples that were drawn 20
days after the first and not later than 2 days after the second Hib vaccine dose were
eligible. Oligosaccharides derived from Hib polysaccharides conjugated to human
serum albumin (HbOHA, NIBSC, Potters Bar, UK) served as coating antigens, and
serum pool lot 1983, received from the Centre for Biological Evaluation & Research
(CBER), Bethesda, MD, USA, served as a reference (Mäkelä et al., 2003).
Fecal analyses
For the fecal studies, parents took samples from their infants’ diapers at home and froze
(-18°C) the samples within 15 minutes and brought the frozen samples in screw-capped
containers to the hospital, where they were stored at -40°C until analyzed.
To assess probiotic bacteria in the feces (I), fecal samples were collected from a
randomly selected sample of 131 infants at birth, and at 3, 6, and 24 months.
Concentrations of lactic acid bacteria were analyzed on MRS agar (LabM, International
Diagnostics Group, Lancashire, UK), and of bifidobacteria on Raffinose-
bifidobacterium agar (Hartemink et al., 1996). Concentrations of the two L. rhamnosus
strains were determined on MRS-vancomycin agar and the concentration of P.
freudenreichii JS on modified YEL agar (Suomalainen and Mäyrä-Mäkinen, 1999). The
detection limit was 103 cfu/g feces. The two Lactobacillus strains and P. freudenreichii
JS strain were identified by random amplified polymorphic DNA (RAPD). The
polymerase chain reaction was performed with the Dynazyme polymerase kit
(Finnzymes, Espoo, Finland), and random primers 5’AGTCAGCCAC3’ and
5’ACGCGCCCT3’ were used for L. rhamnosus GG and LC705, and
5’CGAGCCGTC3’ and 5’AGTCAGCCAC3’ for P. freudenreichii JS. Primers were
used at 3 M and deoxynucleotides at 200 M concentration. Initial denaturizing
occurred at 94oC for 2 min, and a further 40 cycles at 94oC 15 s, at 37oC for 30 s (for L.
rhamnosus GG and LC705); at 30oC for 30 s (for strain JS), and at 72oC for 2 min. The
RAPD bands were separated in 1.5% agarose by gel electrophoresis (Tynkkynen et al.,
1999).
To assess fecal immune markers (IV), samples taken from 237 infants at 3 and 6
months were homogenized with phosphate-buffered saline (PBS; w/v ratio 1:4) on a
shaker for 30 min at +4°C and then centrifuged for 15 min at 10 000 g at +4°C. The
supernatants were stored at -70°C for subsequent analysis. Fecal IgA concentrations
were measured by enzyme-linked immunosorbent assay (see Viljanen et al., 2005a).
Microtiter plates were coated with anti-IgA antibodies diluted to 1:1000 in 50 mM
NaHCO3 pH 9.5, 100 l/well, and held overnight at +4°C. The coated plates were
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washed in PBS and saturated with 2% bovine serum albumin PBS for 1 hour at room
temperature before washing in PBS.  Diluted (1% BSA-0.05% Tween 20-PBS) fecal
extracts were incubated on the plates overnight and then washed 3 times (0.05%
Tween-PBS).  Anti-human IgA conjugated to alkaline phosphatase was added,
incubated for 1 hour, and plates were made as described earlier (Savilahti et al., 1993).
The detection limit was 5µg IgA/L. Fecal 1-AT was determined by a single radial
immunodiffusion method. The antiserum (Orion Diagnostica, Espoo, Finland) was
diluted to 1:37.5 in the agar. Diffusion was allowed to occur for 1 wk at +4°C. The
detection limit was 80 µg/g. TNF-  was measured by the Quantikine HS TNF-
Immunoassay kit (R&D Systems, Inc., Minneapolis, MN, USA) with a detection limit
of 5 pg/g. Fecal calprotectin was measured with an enzyme immunoassay (Phical Test;
Valpro AS, Oslo, produced by NovaTec Immunodiagnostica, Dietzenbach, GmBH,
Germany) with a detection limit of 9.75 µg/g. All samples were analyzed in duplicate.
4.2 Statistical analyses
4.2.1 Sample size calculation
The sample-size calculation of the main study was based on an expected 40%
cumulative incidence of allergic diseases at the end of the 5-year follow-up. To detect a
10% absolute reduction (Odds ratio, OR, 0.64) by probiotics at 5% significance level
and with 90% power, the estimated size of each group allowing a 20% drop-out was
597. The sample size in Studies III and IV was based on the number of available
samples.
4.2.2 Randomization and blinding
The statistician performed computer-generated block randomization of the probiotic and
placebo groups and sent a blinded randomization list (groups A and B) to the supplier
(Valio Ltd).  At 35 weeks of gestation, the supplier mailed the products for the mothers
for their use during pregnancy and for the infants’ use during 3 months. The supplier
brought the products for the infants’ use over 3 to 6 months to the hospital for the
infant’s 3-month visit. The randomization code was kept in a sealed envelope, retained
by the database consultant, who recoded the letters A and B before each analysis. All
comparisons between treatment groups were double-blinded. The database consultant
revealed the randomization key to the statistician only after data management of the
analyses. The clinicians and other study personnel had no access to the randomization
codes before completing the 5-year follow-up.
4.2.3 Outcome measures
In Study I, the primary outcome measure was the cumulative incidence of any allergic
disease or any atopic (IgE-associated) disease at the age of 2 years; the secondary
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outcome measures were eczema and IgE-sensitization. Study II presents the long-term
safety data of the intervention from birth to the age of 2 years. The outcome measures
were neonatal morbidity, reasons for termination of the intervention, adverse events,
growth (length, weight, and head circumference), incidence of infections, and use of
antibiotics. In Study III, the outcome measures were mean, detectable, and protective
antibody concentrations against diphtheria, tetanus, and Hib at the age of 6 months. In
Study IV, the primary outcome was the association of fecal immune markers at 3 and 6
months with allergic diseases and IgE-sensitization at 2 years. Fecal immune markers
served as dependent variables in relation to probiotic treatment and as independent
variables in relation to allergic diseases and IgE-sensitization.
4.2.4 Statistical analyses
In Study I, logistic regression analysis served to compare the cumulative incidences of
allergic diseases between the probiotic and the placebo group at the end of the 2-year
follow-up. The results are given as ORs with 95% confidence intervals (CI). Potential
confounders were first explored by the Breslow-Day test, and stratified analyses were
then performed. Multivariable logistic regression was used to adjust the outcomes for
possible confounders (gender, delivery, duration of breast-feeding, use of antibiotics,
and use of probiotics after intervention). Fecal bacterial counts in the treatment groups
were compared by Mann-Whitney U-test and colonization differences by the Chi-
square test. The results are given as risk ratios and 95% confidence intervals.
To compare data with skewed distributions between the probiotic and placebo
groups, we used the independent samples t-test on the logarithmically transformed data:
serum IgE concentrations (I), the number of infections and antibiotic courses (II),
vaccine antibody concentrations (III), and fecal immune markers (IV). The results
appear as the probiotic: placebo ratios with 95% confidence intervals. For undetectable
concentrations of vaccine antibodies (III) and of fecal markers (IV), we applied the
detection limit divided by 2.
In Study II, the Chi-square test was used to compare categorized or dichotomized
conditions between groups. Weight, height, and head circumference were converted to
SD scores by Pediator® software using the data on Finnish children as the reference
and then analyzed with the t-test for independent samples.
In Study III, univariate logistic regression served to compare the study groups with
respect to the prevalence of detectable and protective Hib antibody concentrations.
Potential confounding factors were tested by the Mantel-Haenszel method and Breslow-
Day test, and then the group comparisons were adjusted by stepwise logistic regression.
In the adjusted group comparisons, in the beginning, the study group was forced to the
model with probability for variables to enter F 0.05 and to be removed F 0.10.
The nested case-control study design was applied in Study IV, where infants with an
allergic disease or sensitization (cases) were compared with healthy controls (no
allergic diseases and not sensitized). The immune marker concentrations (at 3 and 6
months) were divided into tertiles, and then their association with allergic diseases was
analyzed by univariate logistic regression. The possible confounding variables
(probiotic treatment, gender, duration of breastfeeding) were included as categorical
covariates. The results are given as odds ratios with 95% confidence intervals. We used
ANOVA for repeated measures to analyze time-effect and interaction, and analysis of
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variance (2-ANOVA), where antibiotic treatment during the intervention was included
as a categorical covariate. Correlations between fecal IgA and inflammatory markers
were assessed separately for the 3- and 6-month measurements and for both
measurements concomitantly by the correlation method according to Bland & Altman
(1995).
Data were analyzed by SPSS, version 13.0 (I), 14.0 (II), 12.0 (III), or 15.0 (IV)
(SPSS Inc, Chicago, IL, USA).
4.3 Ethics
Each mother signed a written informed consent which ensured that she could reject any
part of the study when desired without consequences for her child’s care. The ethics
committee of the Hospital for Children and Adolescents of Helsinki University Central
Hospital approved the study protocol. Financial support was provided by Valio
Research and Development through the independent Helsinki University Hospital
Research Institute, but without financial benefit to the researches.
Probiotics, which are generally considered safe, are being consumed in increasing
amounts also during pregnancy and childhood in developed coutries. Prebiotics were
administered in amounts too low to cause abdominal discomfort. The study products
fulfilled the quality requirements for probiotic bacteria, and all infants were carefully
monitored by the study group. The study pediatrician was available for consultations on




Of the 1223 randomized mothers, 156 (13%) discontinued during pregnancy before the
birth of the child. Of the newborn infants, 63 (including 14 B-twins) were ineligible
(Figure 4). Of the 45 premature infants, 30 were born before initiation of the treatment,
and 8 infants in the probiotic and 7 in the placebo group were born prematurely to
mothers who had already begun the intervention. The intention-to-treat probiotic group
included 506 infants, and the intention-to-treat placebo group included 512. Compliance
for the intention-to-treat infants was similar in both our treatment groups with a mean
161 (±50) treatment days for the probiotic and 162 (±48) for the placebo group. The
80% compliance level ( 144 treatment days) was 88% in both groups. Seven infants in
the probiotic and 13 on the placebo consumed commercially available probiotics during
the intervention— against the protocol. No commercially available regular infant
formula containing pro- or prebiotics was available. Of the intention-to-treat infants, a
total of 939 (92%) infants completed the 6-month and 925 (91%) the 2-year follow-ups.
All analyses were based on the intention-to-treat population. For infants’ baseline
characteristics for Studies I to IV, see Table 3.










Number of infants 925 461 464 506 512 47 40 120 117
Males (%) 49 50 49 50 49 55 58 52 43



















Cesarean section (%) 17 17 17 17 17 11 15 19 22
Maternal smoking after
pregnancy (%)
14 16 13 16 13 15 12 13 8
Partially breast-fed 6
months (%)
69 71 68 71 68 67 55 72 72
Duration of breast-feeding
months (±SD)
8.4 8.6±5.4 8.2±4.9 8.6±5.4 8.2±5.0 8.3±5.4 8.0±5.2 8.8±5.2 8.9±4.9
Initiation of solid foods
months (±SD)
4.0 4.0±0.8 4.0±0.7 4.0±0.8 4.0±0.7 4.0±0.8 4.0±0.7 3.9±0.7 4.0±0.7
Attending day care center
<2 years (%)
50 50 51 50 51 57 54 52 50
First-born child in the
family (%)
55 58 52 58 52 47 62 65 56
Maternal allergy (%) 81 80 81 81 81 74 80 78 79
Both parents allergic (%) 38 38 38 38 38 42 48 42 44









Mothers assigned to probiotic
group (610)

























2-year follow-up of infants
Clinical examination (464)
Questionnaire (472)

















Skin prick test (449)
Fecal colonization (47)
Fecal inflammatory markers (120)
Vaccine antibodies (47)
6-month follow-up
Clinical examination  (470)
Questionnaire (471)
Skin prick test (456)
Fecal colonization(52)
Fecal inflammatory markers (117)
Vaccine antibodies (40)
12-month questionnaire (468) 12-month questionnaire (474)
Mothers assessed for eligibility
(1521)
Figure 4 Flow of participants
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5.2 Allergic diseases and sensitization (I)
5.2.1 Main outcome
The cumulative incidence of any allergic disease (food allergy, eczema, asthma or
rhinitis) at age 2 years was 33%. The cumulative incidence of eczema was 29%, food
allergy 8%, asthma 3%, and rhinitis 1%. An open food-challenge was performed on
13% of all infants whose food-related symptoms disappeared during a 2-week
elimination diet.
Probiotic treatment compared to placebo had no significant effect on the appearance
of any allergic disease by age 2. However, probiotic treatment compared to placebo
tended to reduce atopic (IgE-associated) diseases (P=0.052). The outcomes were
adjusted by means of multivariate logistic regression for sex, delivery by cesarean
section, any breast-feeding for at least 6 months, and the use of antibiotics during the
intervention, and regular (daily or 2 days a week) consumption of probiotics.
Compared to placebo, the adjusted risk for any allergic disease by probiotics was OR
0.82 (95% CI 0.61 to 1.08; P=0.159) and for any atopic (IgE-associated) disease 0.65
(0.45 to 0.94; P=0.022). The relative risk reduction for any atopic disease by probiotics
was 29% (adjusted 35%).
Of infants suffering from any allergic disease, 88% had eczema. The cumulative
incidence of eczema was lower in the probiotic than in the placebo group, 26% vs. 32%
(P=0.035). Atopic (IgE-associated) eczema occurred in 92% of children suffering from
any atopic disease. The cumulative incidence of atopic eczema was significantly lower
in the probiotic than in the placebo group, 12% vs. 18% (P=0.025). Compared to
placebo, the adjusted risk for eczema with probiotics was 0.69 (0.52 to 0.93; P=0.015)
and for atopic eczema 0.61 (0.42 to 0.90; P=0.012). The relative risk reduction for
eczema was 26% (adjusted 31%) and for atopic eczema 34% (adjusted 39%). The
number needed to treat was 16 for eczema and 19 for atopic eczema.
Between the probiotic and placebo groups, sensitization rates did not differ
significantly: 28% vs. 31%. The adjusted OR was 0.82 (0.61 to 1.10; P=0.184) (Table
4).




(%) OR 95% CI P
Allergic disease 31.5 35.1 0.85 0.64 to 1.12 0.236
Atopic disease 14.0 18.8 0.71 0.50 to 1.00 0.052
Eczema 26.0 32.3 0.74 0.55 to 0.98 0.035
Atopic eczema 12.4 17.7 0.66 0.46 to 0.95 0.025
Sensitization 28.0 31.2 0.86 0.65 to 1.14 0.289
Food allergy 7.6 8.0 0.95 0.59 to 1.53 *0.902
Asthma 3.0 3.4 0.89 0.42 to 1.82 *0.853
Allergic rhinitis 1.3 1.5 0.86 0.23 to 2.58 *1.000
*Fisher’s exact test
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5.2.2 Other clinical parameters and sub-group outcomes
Sensitization rates in the two study groups as measured by skin prick test to egg white
at 6 months of age were comparable. Serum total-IgE concentrations did not differ
significantly between probiotic and placebo groups, but were significantly higher
among boys than girls, geometric mean (95% CI) 33.6 (28.9 to 39.1) vs. 20.8 (17.8 to
24.4) kU/, OR 0.62 (0.50 to 0.77; P<0.001). Mean (95% CI) SCORAD index among
infants with diagnosed eczema by age 2 years was 20.1 (17.5-22.6) in the probiotic and
20.5 (18.2-22.7) in the placebo group. Among boys, the relative risk reduction for
atopic eczema was 41% (Table 5). In infants receiving exclusively breast-milk 4
months, some allergic disease occurred in 58 of 182 (32%) in the probiotic and 75 of
180 (42%) in the placebo group, OR 0.65 (0.43 to 1.01; P=0.053), and some atopic
disease occurred in 22 of 181 (12%) vs. 38 of 179 (21%), OR 0.51 (0.29 to 0.91;
P=0.021), respectively.
Table 5. Other clinical parameters and sub-group outcomes at age of 2 (years)
Outcome Probiotic N=461 Placebo N=464 OR 95% CI P
Egg SPT-positive 6 months (%) 12.7 13.6 0.92 0.63 to 1.36 0.556
Total IgE (kU/L)* 25.7 (22.2-29.8) 27.2 (23.1-32.0) 0.95 0.76 to 1.18 0.626
Total IgE (kU/L) in boys* 31.3 (25.2-39.0) 36.1 (29.3-44.4) 0.87 0.67 to 1.17 0.360
Sensitized boys (%)† 29.8 [67/225] 35.0  [79/226) 0.79 0.53 to1.17 0.268
Atopic eczema in boys (%)† 12.2 [28/229] 19.0 [43/226] 0.59 0.35 to 0.99 0.046
 *Geometric mean (95%CI), † Sample size in brackets
5.3 Recovery of probiotic bacteria in the feces (I)
Meconium samples contained bifidobacteria in both the probiotic (18%) and the
placebo (11%) group but contained no lactobacilli or propionibacteria. During the 6-
month intervention, geometric mean amounts of fecal lactobacilli, bifidobacteria, L.
rhamnosus GG, L. rhamnosus LC705, and Propionibacterium freudenreichii JS
shermanii  were significantly higher in the probiotic than in the placebo group (repeated
measurements ANOVA, P<0.001 for each strain). At 2 years, however, fecal recovery
of the studied probiotics in the two study groups was comparable (Figures 5 and 6).
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Fecal counts of probiotic bacteria (cfu)












Fecal counts of LGG, L. rhamnosus LC705,
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Figure 5 Recovery of probiotic bacteria in the feces. Total log10 counts of
fecal a. Lactobacilli and bifidobacteria b. L. rhamnosus GG (LGG), L.
rhamnosus LC705 (LC705), and Propionibacterium freudenreichii JS shermanii
(PJS) in probiotic (black) and placebo (gray) groups. Significances between
probiotic and placebo groups *P<0.001, †P=0.002 . The number of samples in
the probiotic group was 61 at birth and 47 at 3, 6, and 24 months, and in the





















Figure 6 Prevalence of the probiotic bacteria, L. rhamnosus GG (LGG), L.
rhamnosus LC705 (LC705), and Propionibacterium freudenreichii JS shermanii
(PJS), in fecal samples at 6 and 24 months. Significances between probiotic and
placebo groups were P=0.036 for all bifidobacteria and P<0.001 for the other
bacteria. At 2 years, no significant differences occurred. The number of samples




Between the probiotic and placebo groups, neonatal morbidity, according to parental
reports, was comparable (Figure 7) in terms of antibiotic treatment due to suspected or
verified infection, jaundice requiring phototherapy, hypoglycemia requiring glucose
infusion, or oxygen supplementation after birth.
5.4.2 Infantile colic and defecation
In both the probiotic and the placebo group, infantile colic (crying 4 hours per day, on
3 days a week) occurred in 4%. Crying 4 hours per day once or twice weekly
occurred in 10%. Defecation of 3 times daily was less frequent in the probiotic group
(18% vs. 29%; P<0.001).
5.4.3 Tolerance and adverse events
In the probiotic and placebo groups, feeding-related symptoms occurred similarly:
abdominal discomfort (6.9 vs.7.2%), excessive vomiting (1.4% vs. 2.3%), and excessive
crying (2.6 vs. 1.8%). Of all the families, 3.2% (3.2% vs. 3.3%) considered the
treatment protocol difficult to follow, and for 0.6% (0.4% probiotic, 0.8% placebo)
infants they discontinued the treatment due to major difficulties in swallowing of the
powder. One infant who experienced a choking event associated with ingestion of the
powder recovered completely. In both study groups, symptoms causing discontinuation
of the intervention were equally frequent. Any reason for hospitalization after discharge
from the maternity hospital up to 2 years of age was unlikely to be related the
intervention (Figure 8).
5.4.4 Growth
Infants in both the probiotic and the placebo group grew normally. The mean (±SD)
length at 6 months was 68.4±2.4 cm in both groups, and at 2 years 88.4±3.2 cm in the
probiotic vs. 88.6±3.1 cm in the placebo group. In these respective groups, the mean
(±SD) weight at 6 months was 8.16±0.98 vs. 8.09±0.95 kg and at 2 years 12.8±1.5 vs.
12.8±1.4 kg. Head circumference mean (±SD) was 35.3±1.4 in the probiotic and
35.2±1.5 in the placebo group at birth, 43.9±1.3 in both of the groups at 6 months, and
49.4±1.5 vs. 49.5±1.7 at 2 years. Figures for length, weight, and head circumference
between the probiotic and placebo groups at every measurement were comparable.
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Neonatal morbidity
















Figure 7 Neonatal morbidity according to parental reports among intention-
to-treat infants Infection: received antibiotics for verified or suspected neonatal
























Figure 8 Serious adverse events according to parental reports during the
first 2 years of life. *Other diagnosis included surgery (aortic coarctation, patent
ductus arteriosus, ventricular septal defect, testis retention, cleft palate, ductus
thyreoglossus), neonatal hepatitis, meconium plug obstruction, growth hormone
deficiency, celiac disease, and gastroesophageal reflux
5.4.5 Common infections and antibiotic use
During the intervention (0 to 6 months), the proportion of infants in the probiotic and
placebo groups suffering from any respiratory infection, middle ear infection, or
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gastroenteritis was comparable (Table 6a). During the follow-up period between 6 and
24 months, the number of infants suffering from any respiratory infection was
significantly lower in the probiotic group (P=0.023) (Table 6a). During the follow-up
period between 6 and 24 months of age, significantly fewer episodes of respiratory
infections in the probiotic than in the placebo group (P=0.009), and probiotics tended to
reduce the total number of middle ear infections (P=0.068) (Table 6b). From birth to
age 2, 99.5% of all children were reported to have suffered at least once from middle
ear or other respiratory infection.
During the intervention (0 to 6 months), fewer infants received antibiotics in the
probiotic (23%) than in the placebo group (28%) (P=0.049). However, after the
intervention, most infants received antibiotics, with no significant differences between
the probiotic (80%) and the placebo (83%) group (Table 6, Figure 9).
Table 6 a. Occurrence (at least once) of infections and antibiotic courses during the
intervention (0 to 6 months) and after the intervention (6 to 24 months)
Table 6 b.  Number of infections and antibiotic courses after the intervention from 6 months
to age 2   years













Ear infection 15 19 0.179 72 76 0.204
Respiratory  infection 66 68 0.678 93 97 0.023
Gastroenteritis 13 14 0.664 74 71 0.345
Antibiotic use 23 28 0.049 80 83 0.249
Probiotic N=468 Placebo N=471
Geometric mean Geometric mean Ratio 95% CI P
Ear infection 1.7 1.9 0.89 0.78 to 1.01 0.068
Respiratory infection 3.7 4.2 0.87 0.79 to 0.97 0.009
Gastroenteritis 1.3 1.2 1.02 0.92 to 1.12 0.736
Antibiotic use 2.2 2.4 0.92 0.81 to 1.05 0.206
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Probiotic vs. Placebo (OR, 95% CI)






Probiotic vs. Placebo (OR, 95% CI)
Figure 9 Risk for occurrence (  once) of infections and antibiotic courses
during intervention (0-6 months) and during follow-up (6-24 months)
5.5 Vaccine antibody responses (III)
The probiotic treatment had no deleterious effect on vaccine antibody responses. In the
probiotic group, the geometric mean Hib IgG concentration tended to be higher, but the
difference was non-significant. Anti-Hib antibodies were detectable in 21 of 32 (66%)
in the probiotic group, and in 14 of 29 (48%) in the placebo group (P=0.174).
Protective anti-Hib IgG concentrations ( 1 µg/ml) occurred more frequently in the
probiotic group, 16 of 32 (50%), than in the placebo group, 6 of 29 (21%), OR 3.83
(1.23 to 11.92; P=0.020).  None of the 7 infants (3 probiotic, 4 placebo) vaccinated
with the HbOC conjugate showed an anti-Hib response. Hib antibodies in PRP-T-
vaccinated infants exceeded 1 µg/ml in 16 of 29 (55%) in the probiotic vs. 6 of 25
(24%) in the placebo group, OR 3.90 (1.20 to 12.61; P=0.023). Differences in the
geometric mean concentrations of anti-diphtheria IgG and of anti-tetanus IgG between
the study groups were non-significant. In all infants, diphtheria and tetanus IgG titers
exceeded the protective level of 0.01 IU/ml (Table 7).
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Table 7. Serum antibody concentrations at 6 months of age for infants vaccinated against
tetanus, diphtheria, and Haemophilus influenzae type b(Hib)
Probiotic N=47 Placebo  N=40
Geometric mean (95% CI) Geometric mean (95%CI) †Ratio 95% CI P
Diphtheria IU/ml 0.38 (0.14 to 0.78) [37] 0.47 (0.19 to 1.40) [37] 0.80 0.45 to 1.43 0.449
Tetanus  IU/ml 1.01 (0.47 to 1.49) [37] 0.81 (0.56 to 1.39) [37] 1.23 0.82 to 1.86 0.310
Hib µg/ml* 0.75 (0.15 to 2.71) [32] 0.40 (0.15 to 0.92) [29] 1.87 0.96 to 3.64 0.064
*Sample size in brackets, † ratio probiotic:placebo
5.6 Mucosal immune markers (IV)
5.6.1 Fecal immune markers in predicting allergies
In Study IV, of the 124 infants with an allergic disease or sensitization (cases), 117
were sensitized and 99 manifested an allergic disease. The control group comprised the
113 healthy non-sensitized infants. The geometric mean fecal IgA or fecal inflammatory
markers were comparable between the cases and controls (data not shown).
Having a high fecal IgA concentration at age 6 months tended to reduce the risk for
cumulative incidence of any allergic disease by age 2. Furthermore, the high fecal IgA
reduced risk for any atopic (IgE-associated) disease (P for trend=0.044) (Table 8).
Increased fecal IgA (T2 compared to T1) reduced risk for eczema, OR 0.44 (0.22 to
0.91; P=0.026) and atopic (IgE-associated) eczema, OR 0.47 (0.23 to 0.99; P=0.039) at
2 years of age.
Fecal IgA concentrations correlated with concentrations of all the fecal
inflammation markers; IgA vs. 1-AT (r=0.68; P<0.001), IgA vs. TNF-  (r=0.30;
P<0.001) and IgA vs. calprotectin (r=0.66; P<0.001).
TNF-  and 1-AT in allergic and healthy infants (data not shown) were comparable.
Having high fecal calprotectin at the age of 6 months seemed to associate with reduced
risk for atopic diseases at age 2 years (T3 compared to T2), OR 0.49 (0.25 to 0.98;
P=0.044).
5.6.2 Effects of probiotics on fecal immune markers
Probiotic treatment, compared to placebo, tended to raise geometric mean fecal IgA and
TNF- , and significantly raised 1-AT (P=0.001) at the age of 3 months, but these
differences disappeared with age (Figure 10). Antibiotic treatment was a confounding
factor; the probiotic effect on IgA, TNF- , and 1-AT was apparent only among infants
without any antibiotic use during the intervention. When adjusted for antibiotic use,
fecal calprotectin at the age of 6 months was significantly higher in the probiotic group
(P=0.045). In all infants, the immune markers decreased from 3 to 6 months of age
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(P<0.001), with a more pronounced reduction of the initially higher 1-AT (P=0.055)
and TNF-  (P=0.034) in the probiotic group (Figure 10).
Table 8.   Association of fecal IgA and calprotectin concentrations at 6 months with risk
for allergic diseases and sensitization by age. The lowest tertile group (T1) is the
reference group in all logistic regression analyses.
Tertiles: IgA ug/ml 3 months <1420.68, 1420.68-2196.57, >2196.57, 6 mo<711.85,
711.85-1235.13, >1235.13 Calprotectin ug/g 3 mo <123.76, 123.76-259.34, >259.34, 6
mo <20.46, 20.46-51.00. Global P-value for trend is adjusted for probiotic intervention
F-IgA























































Figure 10 Fecal concentrations of IgA, calprotectin, 1-antitrypsin, and
tumor necrosis factor-  (TNF- )  at 3 and 6 months of age in infants receiving
pro- and prebiotics (n= 120) or placebo (n= 117)






% OR   95% CI             (P) % OR   95% CI             (P) % OR   95% CI             (P)
IgA T1 61 1.00                     (0.294) 59 1.00                     (0.059) 58 1.00 (0.044)
T2 50 0.65  0.34 to 1.25 41 0.46  0.23 to 0.92 39 0.44  0.21 to 0.90
T3 49 0.63  0.33 to 1.22 43 0.51  0.26 to 1.02 40 0.48  0.24 to 0.96
T1 57 1.00                     (0.376) 54 1.00                     (0.272) 52 1.00                     (0.170)
Calprotectin T2 54 0.87  0.46 to 1.64 48 0.82  0.42 to 1.59 47 0.86  0.44 to 1.71





The results of this study apply to urbanized high-risk infants in a high-income country.
Selection of high-risk families was based on telephone interviews by trained personnel,
because allergy testing during pregnancy is unreliable and not recommended. The
unexpectedly high (17%) drop-out rate before initiating the infant’s intervention was
due to the refusal of mothers to participate or to the ineligibility of their newborn infants
(premature, major malformations). We considered an intervention during pregnancy
crucial to the probiotic effect because bacteria in the mother’s intestine colonize the gut
of a newborn infant during vaginal delivery. An additional study visit at 35 gestational
weeks before randomization might have helped us to avoid randomizing mothers not
sufficiently motivated and thus to lower the initial withdrawal. Although some parents
considered the study protocol difficult to follow, the 8% drop-out rate thereafter, during
the 2-year follow-up, was low. High compliance rates and high rates of discovery of
supplemented bacteria in the infants’ feces indicate the success of the intervention and
good adherence to treatment. High follow-up rates may also speak for our trained
personnel, who were ready to counsel and support the families throughout the study.
The sample-size calculation allowed a 20% drop-out and accordingly, the sample size in
Studies I and II was adequate.
Our intervention included a combination of probiotics and prebiotic galacto-
oligosaccharides. Both probiotics and prebiotics had been studied separately before, but
to the best of out knowledge, a similar intervention using their combination had not
been performed previously. By choosing a combination we aimed to broadly stimulate
the mucosal immune system. However, evidence accumulated during the study of
strain-specificity and of probiotic interactions in the mixtures. Although individual
strains in the mixture proved immunologically active, and their combinations had been
synergistic in vitro  (Collado et al., 2007; Rolfe, 2000), clinical studies on their
effectiveness in the treatment of eczema appeared only after initiation of this study
(Viljanen et al., 2005c). We used prebiotics in order to enhance the growth and activity
of probiotics in the gut and aimed at synergistic action. In view of the content of
oligosaccharides in human breast milk (>0.8g/100ml) or of the 0.8g/100ml used in a
prebiotic allergy-prevention trial with formula-fed infants, however, our total daily
amount of 0.8g was low (Moro et al., 2006). We chose a low dose to avoid undesirable
gastrointestinal symptoms caused by large quantities of prebiotics, but the significance
of such a low dose in a population of breast-fed infants can be argued (Tuohy et al.,
2005).
We used opened capsules containing probiotics in powder in order to guarantee the
viability of the bacteria. Although parents were given illustrated instructions to mix the
powder with an adequate amount of liquid, administration of the powder caused a
choking event in one infant. Therefore, if probiotics are administered as a powder,
parents should receive thorough instructions to mix it with sufficient amounts of liquid.
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The 6-month duration of our intervention was based on a previous study with the
hypothesis of a relatively short post-natal time-window in shaping of the immune
system towards non-allergy (Garn and Renz, 2007). However, the immune system is
tuned towards allergy also later in life, for example, allergic diseases and sensitization
occur increasingly in people moving from low to high allergy-prevalence countries or
from rural to urban environments (Viinanen et al., 2007). Thus, in the light of the
current evidence, the duration chosen may have been insufficient.
6.1.2 Diagnostic criteria of allergic diseases
Diagnostic criteria of our clinical outcome measures were based on internationally
accepted guidelines or consensus reports and followed the recommendations of the
European Academy of Allergy and Clinical Immunology for diagnostic criteria for
dietary allergy-prevention trials (Muraro et al., 2004). We used the UK Working Party’s
diagnostic criteria for eczema, the most extensively validated criteria available
(Brenninkmeijer et al., 2008). Although their sensitivity may be lower than are other
criteria frequently used, their specificity is high, and their application in a clinical trial
is— straightforward (Williams et al., 1994). The primary outcome measure chosen was
the cumulative incidence of any allergic disease. Although allergies are a heterogeneous
group of hypersensitivity-type inflammatory diseases with various backgrounds,
probiotics may, according to the current hypothesis, promote immune homeostasis
through several pathways (Freitas et al., 2003). As the pathogenesis and prognosis of
allergic diseases associated with IgE-sensitization differ from those of non-IgE-
associated diseases, defining our secondary outcome measures according to
sensitization was reasonable.
Our cumulative incidences were higher than in unselected cohorts, but did not
exceed the highest reported frequencies of high-risk populations. However, information
is scant as to the incidence of allergic diseases and as to sensitization in high-risk
populations with diagnoses based on doctors’ diagnoses instead of on parental reports.
Eczema is the most common manifestation of allergies in early life. The 32%
cumulative incidence of eczema in our placebo group was higher than the 16%
cumulative prevalence of eczema reported for  unselected Finnish children at age 5
(Lehtonen et al., 2003), and in line with the 36% for eczema observed in high-risk
Swedish children at age 2 (Abrahamsson et al., 2007). The 8% incidence of food allergy
agrees with previous reports within high-risk populations (Sampson, 2003). Our 3%
incidence of recurrent wheezing with persistent symptoms is in line with the 3%
incidence of frequent wheezing seen in high-risk infants before age 3 years (Ly et al.,
2006). Allergic rhinitis occurs late in the atopic march, and clear recurrent symptoms by
age 2 years are unlikely to appear. That incidences other than of eczema were still low
at the age of 2 years did not allow comparisons. The 30% sensitization rate at 2 years in
this study was clearly higher than previously reported for unselected birth-cohorts (Høst
and Halken, 2000), indicating successful selection of a high-risk population.
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6.1.3 Questionnaires
In Study II, use of diaries in addition to structured questionnaires, interviews, and
parental reports would have added value to our tolerance and safety analyses. Diaries
would have been useful in evaluating the probiotic effects on duration and severity of
childhood infections. However, diaries were not included in hopes of enhanced
compliance during the long follow-up period, but the frequent questionnaires, visits, and
recommendations to contact the study personnel were considered adequate.
6.1.4 Blood and fecal samples
Results of Studies III and IV should be interpreted in light of the fact that sample sizes
were based on the samples available. The small sample size in Study III limits its value.
In addition to the changed Hib vaccine, we encountered such problems as a delay in
obtaining ethics-committee permission, parental refusal of blood sampling, and some
failure to follow vaccination schedules. The number of eligible samples was therefore
small, and the results must be interpreted with caution. Selection of fecal samples in
Study IV was based on the presence or absence of allergic diseases or sensitization and
therefore allowed study of fecal immune markers in predicting allergies, but not
primarily the probiotic effect on them.
6.2 Effects of the intervention
6.2.1 Clinical effects
The hypothesis that probiotics and prebiotics will prevent any allergic disease when
given to pregnant mothers and to their high-risk children for the long-term after birth
was not confirmed. However, probiotics did prevent atopic (IgE-associated) diseases
and also eczema, especially when IgE-associated. The majority of infants suffering
from any allergic disease had eczema. Eczema appears early in the atopic march, in the
progressive sequence of allergic diseases leading to airway allergies. IgE-associated
eczema is a strong positive predictive factor for further allergic diseases (Kusel et al.,
2005). Whether prevention of IgE-associated eczema by probiotics predicts fewer
allergic diseases later in life cannot be concluded based on our 2-year follow-up.
Our treatment effect was not as strong as in the first prevention trial, in which L.
rhamnosus GG alone halved the incidence of eczema from 46% to 23% (Kalliomäki et
al., 2001b). Compared to that finding, the 32% cumulative incidence of eczema in our
placebo group was lower, and the relative risk reduction was 26%. In the present study,
we administered the products directly to the newborn infants regardless of mode of
feeding. In the study performed by Kalliomäki et al. (2001b), probiotics were given to
infants only if not breast-fed at all; otherwise the capsules were given to the lactating
mothers. Another difference between the two studies is the probiotic product. Although
our mixture contained similar amounts of the same viable L. rhamnosus GG strain,
other probiotics in our mixture may have modified its effect. In one study where this
same mixture of probiotics was compared to L. rhamnosus GG or placebo, the mixture
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lacked any clinical effect on eczema (Viljanen et al., 2005c). This mixture, when
compared to L. rhamnosus GG,  induced different cytokine profiles and stimulated the
immune system in a different manner (Pohjavuori et al., 2004; Marschan et al., 2008a).
A recently published German study had a relatively small sample size and used the
same L. rhamnosus GG strain as in the Kalliomäki group trial but from another supplier
in smaller amounts (1x1010 vs. 5x109). It reported similar incidences of eczema in the
probiotic and in the placebo group (28% vs. 27%). Although that treatment was initiated
during pregnancy, after delivery, probiotics were given during 6 months for the most
part to lactating mothers instead of direct administration to infants (Kopp et al., 2008b).
The authors saw in vitro  immunological effects (enhanced IL-10 and IFN-  release of
mononuclear cells) from their intervention, but no in vivo effects on cytokine patterns in
the mothers (Kopp et al., 2008a).
In studies showing a positive effect, probiotics have been administered during
pregnancy (Abrahamsson et al., 2007; Kalliomäki et al., 2001b).  Taylor et al. (2007)
used L. acidophilus in high-risk infants, but initiated this intervention after birth.
Colonization of the mother’s intestine before birth has great importance for the infant’s
colonization, at least in infants born vaginally.
Our treatment affected sensitization neither at 6 months nor at 2 years, which is
consistent with the first prevention trial (Kalliomäki et al., 2001b). Except for the
Swedish study reporting trends toward decreased sensitization at 2 years in infants
receiving L. rhamnosus for 12 months from birth, probiotics have not prevented
sensitization (Abrahamsson et al., 2007; Kalliomäki et al., 2001b; Taylor et al., 2007;
Kopp et al., 2008b). IgE-sensitization has been considered a key event in the
pathogenesis of allergic reactions, and its prevention is therefore considered primary
(Asher et al., 2004). Although early sensitization predicts appearance of allergic airway
diseases (Nickel et al., 1997), some sensitized infants remain asymptomatic; hence the
role of IgE in the establishment of allergic diseases remains unclear. The mechanisms of
allergy are more complicated than previously assumed: complex networks of pro- and
anti-inflammatory responses modified by genetic and environmental factors (Freitas et
al., 2003). Probiotics may not affect sensitization per se, but they regulate the path from
sensitization to clinical disease and raise the proportion of asymptomatic infants.
Long-term follow-up in the Kalliomäki group study showed that the cumulative risk
for developing eczema remained reduced in the L. rhamnosus GG group. Children in
the active treatment group had more allergic rhinitis and asthma, but that difference was
non-significant. This does not support the view that probiotics administered during early
life would prevent progress of the “atopic march” (Kalliomäki et al., 2003, 2007).
Our results should be interpreted in the light of the fact that over 70% of the study
infants received breast milk during the 6-month intervention. Although no significant
difference between the study groups occurred, breast-feeding was assessed as a
confounding factor in all the main analyses. Galacto-oligosaccharides and IgA are
plentiful in human milk, and both of them may modulate the risk for allergies and
childhood infections (Brandtzaeg, 2003).
6.2.2 Detection of probiotics in the feces
Infants receiving probiotics showed significantly more frequently and more abundantly
lactobacilli, bifidobacteria, and all the supplemented bacterial strain in their feces, but
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differences in bacterial recovery were temporary. It can be speculated as to why
probiotics fail to colonize permanently (Alander et al., 1999; Kullen and Bettler, 2005).
Inherited features of the host may affect colonization patterns more than environmental
factors do, and certain probiotics have induced immunological responses against
themselves and thereby contributed to the strains’ disappearance (Walker, 2008).
Nevertheless, compared to the Australian study (Taylor et al., 2007), our initial
probiotic colonization, as assessed by the modern PCR 16S rDNA technique, was much
more frequent and was higher. Neither Kalliomäki’s trial nor the two other published
trials reported bacterial colonization of their infants (Kalliomäki et al., 2001b;
Abrahamsson et al., 2007; Kopp et al., 2008b). Although fecal samples are not
representative of the whole mucosa-associated microbiota, the inverse association in our
study between the abundance of certain species of the indigenous gut microbiota and
development of atopic diseases supports the idea of probiotics at least partly
compensating for the delayed immune maturation responsible for establishment of
allergies in genetically prone infants (Wold, 1998).
6.2.3 Safety and infections
Our study indicates that the use of live probiotic bacteria and prebiotic nutrients, even
with long-term administration to newborn infants, carries no risks. Results of Studies II
and III indicate that probiotics improve maturation of the immune system among infants
with atopic heredity. Probiotics improved these infants’ resistance to respiratory
infections: During their first 6 months, they received antibiotics less frequently than did
infants on placebo, and thereafter, to the age of 2 years, they suffered from fewer
respiratory infections. Probiotics also improved their IgG antibody response to the first
dose of Hib polysaccharide vaccine. Our placebo group responded poorly to their first
PRP-T dose (Käyhty et al., 1991), which, in infants with a genetic predisposition to
allergic disorders, may be due to delayed maturation of the immune system (Martinez
and Holt, 1999). The immune-enhancing effects observed are in line with current
knowledge of probiotics’ and prebiotics’ causing increased resistance to common
childhood infections (Hatakka et al., 2001; Weizman et al., 2005; Arslanoglu et al.,
2007).
6.2.4 Fecal IgA and inflammatory markers
Having high fecal IgA at 6 months of age protected against development of atopic
diseases. Again, early immunological differences were evident between the IgE-
sensitized— the true atopics— and healthy controls. By elimination of food antigens in
the intestinal mucosa, IgA reduces antigen load and may thus inhibit manifestation of
symptomatic diseases in such IgE-sensitized infants. Fecal IgA and inflammatory
markers correlated positively. Induction of a subtle physiological inflammation in the
intestinal mucosa may be critical to stimulation of the immune system and to induction
of IgA production (Viljanen et al., 2005b).
High fecal calprotectin at age 6 months inversely associated with atopic diseases.
Calprotectin is a marker of intestinal inflammation (Kolho et al., 2006; Sipponen et al.,
2008), and its concentrations are much higher and more variable in newborn infants
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than in older children or adults (Rugtveit and Fagerhol, 2002). It has been speculated
that the high fecal calprotectin concentrations during the first weeks or months of life
reflect increased granulocyte migration into the gut lumen in response to the initial
establishment of gut microbiota (Rugtveit and Fagerhol, 2002). Commensal bacteria
that colonize the sterile newborn gut induce inflammation, which is balanced by
inhibitory mechanisms and results in development of tolerance. The initially high levels
of inflammation markers and their fading over time may be a physiological response to
the establishment of commensal bacteria and to the presentation of other, and new oral
antigens (O'Farrelly, 1998).
Probiotic intervention was associated with high fecal 1-AT concentrations;
however, these concentrations were 100-fold lower than reported for infants with
manifest food allergy or eczema (Majamaa et al., 1996). In infants suffering from
eczema, both L. rhamnosus GG and the same mixture of probiotics as in this trial have
induced inflammation. However, L. rhamnosus GG seemed to induce more Th1-type
responses, and this mixture promoted regulatory type responses (Viljanen et al., 2005b).
In the blood samples of infants in the same study at age 6 months, the proinflammatory
response associated with probiotics resembled chronic helminth infection-associated
induction of regulatory mechanisms (Marschan et al., 2008b). We suggest that similarly
to commensal bacteria, a subtle inflammation is the mechanism of probiotic bacteria to
support the development of tolerance.
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7. Summary
A mixture of probiotics including Lactobacillus rhamnosus GG (ATCC 53103),
Lactobacillus rhamnosus LC705 (DSM 7061), Bifidobacterium breve Bb99 (DSM
13692), and Propionibacterium freudenreichii ssp. shermanii  JS, along with galacto-
oligosaccharides, was able to prevent eczema, especially atopic eczema. This
combination eventually failed, however, to prevent the development of any allergic
disease or IgE-sensitization by the age of 2 years. Moreover, probiotics with prebiotics
prevented eczema, especially atopic (IgE-associated) eczema. The effect was not as
strong as in the first prevention trial using L. rhamnosus GG alone, but was in line with
findings in recent trials. Whether the positive effect endures and extends to airway
allergies later in life will be explored in follow-up on these same infants.
Probiotic bacteria were recovered in the feces of infants during the supplementation,
but this recovery was temporary.
Probiotic treatment during pregnancy and immediately after birth over the long term
was safe and resulted in normal growth. It seemed slightly to enhance resistance to
common respiratory infections in infants genetically prone to atopy. Probiotics did not
interfere with immune responses to vaccines but improved systemic antigen-specific
IgG antibody responses to Haemophilus influenzae type b polysaccharide vaccine.
These findings need confirmation.
High intestinal IgA in early life predicted fewer atopic (IgE-associated) diseases up
to age 2 years, and correlated positively with intestinal inflammation markers. We
suggest that a low-grade inflammation induces production of mucosal IgA. Probiotics
may induce a low-grade non-symptomatic intestinal inflammation, which may be




Although promising, current evidence as to the efficacy of probiotics and prebiotics in
primary prevention of allergies is conflicting, and their possible preventive effect on
atopic eczema needs confirmation in long-term follow-ups. Probiotic bacteria seem to
beneficially stimulate the maturation of the immune system of atopy-prone infants.
Parents may choose to administer probiotics to their newborn infants, because selected
probiotic bacteria carry no risks.
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